Document:

Form of Registration Rights Agreement

 Exhibit 10.6 
 REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION RIGHTS AGREEMENT (this
“Agreement”) is entered into as of the ____ day of July, 2009, by and among Great American Group, Inc., a Delaware corporation (the “Company”) and the undersigned parties listed under Stockholders on
the signature page hereto (each, a “Stockholder” or “holder” and collectively, the “Stockholders” or “holders”). 
 WHEREAS, certain of the Stockholders owned all of the membership interests of Great American Group LLC, a California limited liability company (“Great
American”); 
 WHEREAS, in connection with that certain Agreement and Plan of Reorganization by and among Alternative
Asset Management Acquisition Corp., a Delaware corporation (“AAMAC”), the Company and wholly-owned subsidiary of AAMAC, AAMAC Merger Sub, Inc. a Delaware corporation and wholly-owned subsidiary of the Company, Great American,
the members of Great American, and the representative of the Company, its subsidiaries, and the Stockholders, dated May 14, 2009, as amended by an Amendment No. 1 to Agreement and Plan of Reorganization dated May 29, 2009 and an
Amendment No. 2 to Agreement and Plan of Reorganization dated July 8, 2009 (collectively, the “Definitive Agreement”), the Company will issue to certain of the Stockholders 12,000,000 newly issued shares of the
Company’s common stock, par value $0.0001 (the “Closing Shares”); 
 WHEREAS, the certain of the
Stockholders may also receive up to 6,000,000 shares of the Company’s common stock, par value $0.0001, upon the Company’s achievement of the financial milestones set forth in the Definitive Agreement (the “Contingent
Shares”, and collectively with the Closing Shares, the “Shares”); 
 WHEREAS, certain of the
Stockholders owned 10,350,000 shares of common stock of AAMAC which, pursuant to the Definitive Agreement, were exchanged for 4,000,000 newly issued shares of the Company’s common stock, par value $0.0001 (the “Founder
Shares”). 
 WHEREAS, the number of Closing Shares held by certain of the Stockholders, the maximum number of Contingent
Shares that may be issued to certain of the Stockholders, the number of Founder Shares held by certain of the Stockholders, are set forth on Schedule I hereto; 
 WHEREAS, the Stockholders may, in certain circumstances and subject to certain transfer restrictions and other restrictions, transfer (or cause to be transferred) to Permitted Transferees (as defined below)
some or all of the Shares or Founder Shares, respectively, held by such Stockholders; and 
 WHEREAS, the Stockholders and the Company
desire to enter into this Agreement to provide the Stockholders with certain rights relating to the registration of the Shares and Founder Shares, respectively, held by them and to provide for any Permitted Transferee who receives Shares or Founder
Shares, respectively, from a Stockholder from time to time to accede to this Agreement. 
 NOW, THEREFORE, in consideration of the
mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. DEFINITIONS. The following capitalized terms used herein have the following meanings: 
 “Adverse Disclosure” means public disclosure of material non-public information, which disclosure, in the good faith judgment of
the chief executive officer or principal financial officer of the Company after consultation with counsel to the Company, (i) would be required to be made in any Registration Statement or Prospectus in order for the applicable Registration
Statement or Prospectus not to contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein (in the case of any Prospectus and any preliminary Prospectus, in the light of the circumstances
under which they were made) not misleading, (ii) would not be required to be made at such time if the Registration Statement were not being filed, and (iii) the Company has a bona fide business purpose for not publicly making it.

 “Agreement” means this Agreement, as amended, restated, supplemented, or
otherwise modified from time to time. 
 “business day” means any day, except a Saturday, Sunday or legal holidays on
which the banking institutions in the State of California are authorized or obligated by law or executive order to close. 
 “Commission” means the Securities and Exchange Commission, or any other federal agency then administering the Securities Act or the Exchange Act. 
 “Common Stock” means the common stock, par value $0.0001 per share, of the Company. 
 “Company” is defined in the preamble to this Agreement and shall include the Company’s successors by merger, acquisition,
reorganization or otherwise. 
 “Demand Registration” is defined in Section 2.1.1. 
 “Demanding Holder” is defined in Section 2.1.1. 
 “Effectiveness Date” means, with respect to the initial Registration Statement required to be filed pursuant to Section 2.3,
the 90th calendar day following the Filing Date (as applicable to the initial Registration Date) (or, in the event of a “full review” by the Commission, the 120th calendar day following such Filing Date) and with respect to any additional
Registration Statements which may be required pursuant to Section 3.1.16, the 90th calendar day following the date on which an additional Registration Statement is required to be filed hereunder; provided, however, that in the
event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the
fifth trading day following the date on which the Company is so notified if such date precedes the dates otherwise required above. 
 “Escrow Agreement” means that certain Escrow Agreement dated as of [            ], 2009 by and among the parties hereto and Continental Stock
Transfer & Trust Company. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations of the Commission promulgated thereunder, all as the same shall be in effect at the time. 
 “Filing
Date” means, with respect to the initial Registration Statement required to be filed pursuant to Section 2.3, the date that is the one-year anniversary following the date that the Company’s initial registration statement on
Form S-4 (or other appropriate form) is declared effective by the Commission and, with respect to any additional Registration Statements which may be required pursuant to Section 3.1.16, the earliest practical date on which the Company is
permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities. 
 “Form
S-3” is defined in Section 2.3. 
 “Indemnified Party” is defined in Section 4.3. 

“Indemnifying Party” is defined in Section 4.3. 
 “Maximum Number of Shares” is defined in Section 2.1.4. 
 “Notices” is defined in Section 7.3. 
 “Permitted Transferee” means (a) immediate family members of a holder and trusts established by a holder for estate planning purposes or (b) affiliates of a holder. 
 “Person” shall be construed as broadly as possible and shall include an individual, corporation, association, partnership
(including a limited liability partnership or a limited liability limited partnership), limited liability company, estate, trust, joint venture, unincorporated organization or a government or any department, agency or political subdivision thereof.

 “Prospectus” means the prospectus included in a Registration Statement
(including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities
Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus,
including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
 “Piggy-Back Registration” is defined in Section 2.2.1. 
 “Register,”
“Registered” and “Registration” mean a registration effected by preparing and filing a registration statement or similar document in compliance with the requirements of the Securities Act, and such
registration statement becoming effective. 
 “Registrable Securities” mean all of the Shares and Founder Shares
beneficially owned or held by Stockholders. Registrable Securities include any warrants, shares of capital stock or other securities of the Company issued as a dividend or other distribution with respect to or in exchange for or in replacement of
such shares. As to any particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a) a Registration Statement with respect to the sale of all such securities shall have become effective under the
Securities Act and all such securities shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement or as may be sold without volume limitations under the Securities Act; (b) all such securities
shall have been otherwise transferred pursuant to Rule 144 under the Securities Act (or any similar rule or regulation then in force), new certificates for them not bearing a legend restricting further transfer shall have been delivered by the
Company and subsequent public distribution of them shall not require registration under the Securities Act; or (c) all such securities shall have ceased to be outstanding. A “percentage” (or a “majority-in-interest”) of the
Registrable Securities (or, where applicable, of any other securities) shall be determined based on the total number of such securities outstanding at the relevant time. 
 “Registration Statement” means a registration statement filed by the Company with the Commission in compliance with the Securities Act (i) for a public (or private) offering and sale (or
resale) of Common Stock, (ii) the registration statement on Form S-4 to be filed in connection with the Definitive Agreement, (iii) the registration statement required to be filed pursuant to Section 2.3, and (iv) any additional
registration statements contemplated herein, including (in each case) the Prospectus, amendments and supplements to such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material
incorporated by reference or deemed to be incorporated by reference in such registration statement. 
 “Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule. 
 “Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act,
as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 
 “SEC Guidance” means (i) any publicly-available written or oral guidance, comments, requirements or requests of the
Commission staff and (ii) the Securities Act. 
 “Securities Act” means the Securities Act of 1933, as amended,
and the rules and regulations of the Commission promulgated thereunder, all as the same shall be in effect at the time. 
 “Stockholder” is defined in the preamble to this Agreement. 
 “Stockholder Indemnified
Party” is defined in Section 4.1. 
 “Underwriter” means a securities dealer who purchases any
Registrable Securities as principal in an Underwritten Offering and not as part of such dealer’s market-making activities. 

 “Underwritten Offering” means a registration in which securities of the Company
are sold to an Underwriter or Underwriters on a firm commitment basis for reoffering to the public. 
 2. REGISTRATION RIGHTS. 
 2.1. Demand Registration. 
 2.1.1.
Request for Registration. Subject to Sections 2.3 and 6.1, at any time and from time to time on or after the first anniversary of the consummation of the acquisition contemplated by the Definitive Agreement (the “Acquisition”), each
of (i) the holders of a majority-in-interest of the Shares held by the Stockholders or the Permitted Transferees of such Stockholders and (ii) the holders of a majority-in-interest of the Founder Shares held by the Stockholders or the
Permitted Transferees of such Stockholders, may make a written demand for registration under the Securities Act of all or part of Registrable Securities held by such holders, provided that the estimated market value of Registrable Securities to be
so registered thereunder is at least $500,000 in the aggregate. Any such requested registration shall be referred to as a “Demand Registration”. Any demand for a Demand Registration shall specify the number of shares of Registrable
Securities proposed to be sold and the intended method(s) of distribution thereof. Within five (5) business days following receipt of any request for a Demand Registration, the Company will notify in writing all holders of Registrable
Securities of the demand, and each holder of Registrable Securities who wishes to include all or a portion of such holder’s Registrable Securities in the Demand Registration (each such holder including shares of Registrable Securities in such
registration, a “Demanding Holder”) shall so notify the Company in writing, provided that such notice shall be received by the Company within ten (10) business days of the Company’s having sent the applicable notice
to such holder or holders. All such requests shall specify the aggregate amount of Registrable Securities to be registered and the intended method of distribution. The Company may include in such registration additional securities of the Registrable
Securities to be registered thereunder, including securities to be sold for the Company’s own account or the account of Persons who are not holders of Registrable Securities. Upon any such request, the Demanding Holders shall be entitled to
have their Registrable Securities included in the Demand Registration, subject to Section 2.1.4 and the provisos set forth in Section 3.1.1. The Company shall not be obligated to effect more than two (2) Demand Registrations (one
(1) with respect to those holders described in clause (i) of this Section 2.1.1 and one (1) with respect to those holders described in clause (ii) of this Section 2.1.1) under this Section 2.1.1 in respect of the
Registrable Securities. 
 2.1.2. Effective Registration. A registration will not count as a Demand Registration until the
Registration Statement filed with the Commission with respect to such Demand Registration has been declared effective and remains effective for not less than 180 days (or such shorter period as will terminate when all Registrable Securities covered
by such Registration Statement have been sold or withdrawn); provided, however, that if, after such Registration Statement has been declared effective, the offering of Registrable Securities pursuant to a Demand Registration is interfered with by
any stop order or injunction of the Commission or any other governmental agency or court, the Registration Statement with respect to such Demand Registration will be deemed not to have been declared effective, unless and until (i) such stop
order or injunction is removed, rescinded or otherwise terminated and (ii) a majority-in-interest of the Demanding Holders thereafter elect to continue the offering. 
 2.1.3. Underwritten Offering. If a majority-in-interest of the Demanding Holders so elect and such holders so advise the Company as part of their written demand for a Demand Registration, the offering of such
Registrable Securities pursuant to such Demand Registration shall be in the form of an Underwritten Offering. In such event, the right of any holder to include its Registrable Securities in such registration shall be conditioned upon such
holder’s participation in such underwriting and the inclusion of such holder’s Registrable Securities in the underwriting to the extent provided herein. The holders of a majority of the Registrable Securities included in such Underwritten
Offering shall, in consultation with the Company, have the right to select the managing Underwriter or Underwriters for the offering, subject to the right of the Company should it so choose to select one co-managing Underwriter reasonably acceptable
to such holders. All Demanding Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such underwriting by a
majority-in-interest of the holders initiating the Demand Registration and consistent with Section 3.2.1. 
 2.1.4. Reduction of
Offering. If the managing Underwriter or Underwriters for a Demand Registration that is to be an Underwritten Offering advises the Company and the Demanding Holders in writing that the dollar amount or number of shares of Registrable Securities
which the Demanding Holders desire to sell, taken together 

 
with all other shares of Common Stock or other securities which the Company desires to sell and the shares of Common Stock, if any, as to which registration
has been requested pursuant to written contractual piggy-back registration rights held by other stockholders of the Company who desire to sell, exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without
adversely affecting the proposed offering price, the timing, the distribution method, or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the “Maximum Number of
Shares”), then the Company shall include in such registration: (i) first, the Registrable Securities as to which Demand Registration has been requested by the Demanding Holders (pro rata among the holders who have requested
participation in the Demand Registration based, for each such holder, on the percentage derived by dividing (x) the number of Registrable Securities which such holder has requested to include in such Demand Registration by (y) the
aggregate number of Registrable Securities which all such holders have requested to include) (such proportion is referred to herein as “Pro Rata”) that can be sold without exceeding the Maximum Number of Shares;
(ii) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (i), the shares of Common Stock or other securities that the Company desires to sell that can be sold without exceeding the Maximum
Number of Shares; (iii) third, to the extent that the Maximum Number of Shares have not been reached under the foregoing clauses (i) and (ii), the shares of Common Stock or other securities for the account of other Persons that the Company
is obligated to register pursuant to written contractual arrangements with such Persons, Pro Rata, and that can be sold without exceeding the Maximum Number of Shares; and (iv) fourth, to the extent that the Maximum Number of Shares have not
been reached under the foregoing clauses (i), (ii), and (iii), securities that other security holders of the Company desire to sell, Pro Rata, that can be sold without exceeding the Maximum Number of Shares. To the extent that any Registrable
Securities requested to be registered are excluded pursuant to the foregoing provisions, the holders shall have the right to one additional Demand Registration under this Section 2.1.4. 
 2.1.5. Withdrawal. A holder may withdraw its Registrable Securities from a Demand Registration at any time. If all holders withdraw, or holders
withdraw Registrable Securities from a Demand Registration in such amounts that the Registrable Securities that remain covered by the relevant Registration Statement have an estimated market value of less than $500,000, the Company shall cease all
efforts to secure registration and such withdrawn registration shall be deemed a Demand Registration for purposes of Section 2.1 unless the withdrawal is based on the reasonable determination of the Demanding Holders that there has been, since
the date of such request, a material adverse change in the business or prospects of the Company or in general market conditions and the Demanding Holders who requested such registration shall have paid or reimbursed the Company for all of the
reasonable out-of-pocket fees and expenses incurred by the Company in connection with the withdrawn registration. 
 2.1.6. Suspension of
Registration. If the filing, initial effectiveness or continued use of a Registration Statement in respect of a Demand Registration at any time would require the Company to make an Adverse Disclosure or would require the inclusion in such
Registration Statement of financial statements that are unavailable to the Company for reasons beyond the Company’s control, the Company may, upon giving prompt written notice of such action to the holders, delay the filing or initial
effectiveness of, or suspend use of, such Registration Statement for the shortest possible period of time determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under the preceding
sentence, the holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating to the Demand Registration in connection with any sale or offer to sell Registrable Securities. The Company
shall immediately notify the holders of the expiration of any period during which it exercised its rights under this Section 2.1.6. The Company shall be entitled to exercise its right under this Section 2.1.6 to suspend the availability of
a Registration Statement for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12 month period. 
 2.1.7.
Registration Statement Form. Registrations under this Section 2.1 shall be on such appropriate registration form of the Commission (i) as shall be selected by the Company and as shall be reasonably acceptable to the holders of a
majority-in-interest of the Registrable Securities requesting participation in the Demand Registration and (ii) as shall permit the disposition of the Registrable Securities in accordance with the intended method or methods of disposition
specified in the applicable holders’ requests for such registration. Notwithstanding the foregoing, if, pursuant to a Demand Registration, (x) the Company proposes to effect registration by filing a Registration Statement on Form S-3,
(y) such registration is in connection with an Underwritten Offering, and (z) the managing Underwriter or Underwriters shall advise the Company in writing that, in its or their opinion, the use of another form of registration statement (or
the inclusion, rather than the incorporation by reference, of information 

 
in the Prospectus related to a Registration Statement on Form S-3) is of material importance to the success of such proposed offering, then such registration
shall be effected on such other form (or such information shall be so included in such Prospectus). 
 2.2. Piggy-Back Registration.

 2.2.1. Piggy-Back Rights. Subject to Sections 2.3 and 6.1, if at any time on or after the date the Company consummates the
Acquisition the Company proposes to file a Registration Statement under the Securities Act with respect to an offering of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities,
by the Company for its own account or for stockholders of the Company for their account (or by the Company and by stockholders of the Company including, without limitation, pursuant to Section 2.1), other than a Registration Statement
(i) filed in connection with an offering of securities to employees or directors of the Company pursuant to any employee stock option or other benefit plan, (ii) filed on Form S-4 or S-8 or any successor to such forms, (iii) for an
exchange offer or offering of securities solely to the Company’s existing security holders, (iv) for an offering of debt that is convertible into equity securities of the Company, (v) for a dividend reinvestment plan, or
(vi) solely in connection with a merger, consolidation or non-capital raising bona fide business transaction (Registration Statements described in clauses (i)-(vi) herein, “Allowable Registration Statements”), then the Company
shall (x) give written notice of such proposed filing to the holders of Registrable Securities as soon as practicable but in no event less than ten (10) business days before the anticipated filing date, which notice shall describe the
amount and type of securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y) offer to the holders of Registrable
Securities in such notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may request in writing within five (5) business days following receipt by such holder of such notice (a
“Piggy-Back Registration”). Subject to Section 2.2.2, the Company shall include in such Registration Statement such Registrable Securities requested to be included therein within five (5) business days after the
receipt by such holder of any such notice, on the same terms and conditions as any similar securities of the Company. If at any time after giving written notice of its intention to register any securities and prior to the effective date of the
Registration Statement filed in connection with such registration, the Company shall determine for any reason not to register or to delay registration of such securities, the Company may, at its election, give written notice of such determination to
each holder of Registrable Securities and, (x) in the case of a determination not to register, shall be relieved of its obligation to register any Registrable Securities in connection with such registration, and (y) in the case of a
determination to delay registering, shall be permitted to delay registering any Registrable Securities for the same period as the delay in registering such other securities. If the offering pursuant to a Piggy-Back Registration is to be an
Underwritten Offering, then each holder making a request for its Registrable Securities to be included therein shall enter into any underwriting agreement requested by the Company in accordance with Section 3.2.1, and the Company shall use
commercially reasonable efforts to cause the managing Underwriter or Underwriters of a proposed Underwritten Offering to permit the Registrable Securities requested to be included in a Piggy-Back Registration on the same terms and conditions as any
similar securities of the Company and other Persons selling securities in such Underwritten Offering and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All
holders of Registrable Securities proposing to distribute their securities through a Piggy-Back Registration that involves an Underwriter or Underwriters shall enter into an underwriting agreement in customary form with the Underwriter or
Underwriters selected for such Piggy-Back Registration. 
 2.2.2. Reduction of Offering. If the managing Underwriter or Underwriters
for a Piggy-Back Registration that is to be an Underwritten Offering advises the Company and the holders of Registrable Securities in writing that the dollar amount or number of shares of Common Stock which the Company desires to sell, taken
together with shares of Common Stock, if any, as to which registration has been demanded pursuant to written contractual arrangements with Persons other than the holders of Registrable Securities hereunder, the Registrable Securities as to which
registration has been requested under this Section 2.2, and the shares of Common Stock, if any, as to which registration has been requested pursuant to the written contractual piggy-back registration rights of other stockholders of the Company,
exceeds the Maximum Number of Shares, then the Company shall include in any such registration: 
 (a) If the registration is undertaken for
the Company’s account: (A) first, the shares of Common Stock or other securities that the Company desires to sell that can be sold without exceeding the Maximum Number of 

 
Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock or
other securities, on a pro rata basis, of Registrable Securities as to which registration has been requested pursuant to this Section 2.2, and (C) third, to the extent that the Maximum Number of Shares has not been reached under the
foregoing clauses (A) and (B), the shares of Common Stock or other securities for the account of other Persons that the Company is obligated to register pursuant to written contractual piggy-back registration rights with such Persons granted
prior to the date hereof, that can be sold without exceeding the Maximum Number of Shares. 
 (b) If the registration is a “demand”
registration undertaken at the demand of Persons other than the holders of Registrable Securities, (A) first, the shares of Common Stock or other securities for the account of the demanding Persons that can be sold without exceeding the Maximum
Number of Shares; (B) second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the shares of Common Stock or other securities that the Company desires to sell that can be sold without
exceeding the Maximum Number of Shares; and (C) third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A) and (B), the shares of Common Stock or other securities, on a pro rata basis, of
(i) Registrable Securities as to which registration has been requested pursuant to this Section 2.2, and (ii) securities for the account of other Persons that the Company is obligated to register pursuant to written contractual
piggy-back registration rights with such Persons granted prior to the date hereof, that can be sold without exceeding the Maximum Number of Shares. 
 2.2.3. Withdrawal. Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable Securities in any Piggy-Back Registration by giving written notice to the Company of such request
to withdraw prior to the effectiveness of the Registration Statement. The Company (whether on its own determination or as the result of a withdrawal by Persons making a demand pursuant to written contractual obligations) may withdraw a registration
statement at any time prior to the effectiveness of the Registration Statement. Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders of Registrable Securities in connection with such Piggy-Back Registration
as provided in Section 3.4. 
 2.3. Registrations on Form S-3. 
 (a) Filing. On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all or such maximum portion of the Registrable Securities as permitted by SEC Guidance (provided that the Company shall use diligent efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance
with the SEC Guidance) that are not then registered on an effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415. The Registration Statement shall be on Form S-3 (except if the Company is not then
eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate form in accordance herewith) (any such form referred to herein as “Form S-3”). Subject to the terms of
this Agreement, the Company shall use its best efforts to cause a Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof, but in any event prior to the applicable Effectiveness Date,
and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act until all Registrable Securities covered by such Registration Statement have been sold, or may be sold without volume restrictions
pursuant to the Securities Act, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Company’s transfer agent and the affected holders of Registrable Securities (the
“Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement as of 2:00 p.m. California time on a trading day. The Company shall immediately notify the holders of Registrable Securities via
facsimile or by e-mail of the effectiveness of a Registration Statement on the same trading day that the Company telephonically confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration
Statement. The Company shall, by 10:00 a.m. California time on the trading day after the effective date of such Registration Statement, file a final Prospectus with the Commission as required by Rule 424. Notwithstanding any other provision of this
Agreement, if any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement (and notwithstanding that the Company used diligent efforts to advocate with the
Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a holder of Registrable Securities as to its Registrable Securities, the number of Registrable Securities to be
registered on such Registration Statement will be reduced by Registrable Securities represented by the Shares and Founder Shares pari 

 
passu (applied, in the case that some Shares and/or Founder Shares may be registered, to the holders of Registrable Securities on a pro rata basis
based on the total number of unregistered Shares and/or Founder Shares held by such holders). Registrations effected pursuant to this Section 2.3 shall not be counted as Demand Registrations effected pursuant to Section 2.1. 
 (b) Suspension of Registration. If the filing, initial effectiveness, or continued use of Form S-3 at any time would require the Company to make
an Adverse Disclosure or would require the inclusion in such Form S-3 of financial statements that are unavailable to the Company for reasons beyond the Company’s control, the Company may, upon giving prompt written notice of such actions to
the holders, delay the filing or initial effectiveness of, or suspend use of, the Form S-3 for the shortest period of time determined in good faith by the Company to be necessary for such purpose. In the event the Company exercises its rights under
the preceding sentence, the holders agree to suspend, immediately upon their receipt of the notice referred to above, their use of the Prospectus relating to the registration on such Form S-3 in connection with any sale or offer to sell Registrable
Securities and agree not to disclose to any other Person the fact that the Company has exercised such rights or any related facts. The Company shall immediately notify the holders upon the expiration of any period during which it exercised its
rights under this Section 2.3(b). The Company will use its best efforts to ensure that the use of the Form S-3 (and Prospectus thereunder) may be resumed as promptly as is practicable. The Company shall be entitled to exercise its right under
this Section 2.3(b) to suspend the availability of a Form S-3 for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12 month period. 
 3. REGISTRATION PROCEDURES. 
 3.1. Filings; Information. Whenever the Company is
required to effect the registration of any Registrable Securities pursuant to Section 2, the Company shall use its best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method(s) of
distribution thereof as expeditiously as reasonably practicable, and in connection with any such requirement: 
 3.1.1. Filing Registration
Statement. The Company shall, as expeditiously as reasonably possible, prepare and file with the Commission a Registration Statement on any form for which the Company then qualifies or which counsel for the Company shall deem appropriate and
which form shall be available for the sale of all Registrable Securities to be registered thereunder in accordance with the intended method(s) of distribution thereof, and shall use its best efforts to cause such Registration Statement to become and
remain effective for the period required by Section 3.1.3; provided, however, that the Company shall have the right to defer any Demand Registration for up to thirty (30) calendar days, and any Piggy-Back Registration for such period as
may be applicable to deferment of any demand registration to which such Piggy-Back Registration relates, in each case if the Company shall furnish to the holders a certificate signed by the Chairman of the Board or Chief Executive Officer of the
Company stating that, in the good faith judgment of the Board of Directors of the Company, it would be materially detrimental to the Company and its stockholders for such Registration Statement to be effected at such time; provided further, however,
that the Company shall not have the right to exercise the right set forth in the immediately preceding proviso more than once in any 365-day period in respect of a Demand Registration hereunder. 
 3.1.2. Copies. Not less than 3 trading days prior to the filing of each Registration Statement and not less than one trading day prior to the
filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed to be incorporated therein by reference) the Company shall furnish without charge to the holders of Registrable
Securities included in such registration, and such holders’ legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case including all exhibits thereto
and documents incorporated by reference therein), the Prospectus included in such Registration Statement (including each preliminary Prospectus), and such other documents as the holders of Registrable Securities included in such registration or
legal counsel for any such holders may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such holders; provided, that any such item which is available on the EDGAR system need not be furnished in
physical form. 
 3.1.3. Amendments and Supplements. The Company shall use best efforts to prepare and file with the Commission such
amendments, including post-effective amendments, and supplements to such Registration 

 
Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and in compliance with the
provisions of the Securities Act during the Effectiveness Period or such securities have been withdrawn. 
 3.1.4. Notification. After
the filing of a Registration Statement, the Company shall as soon as reasonably practical, notify the holders of Registrable Securities included in such Registration Statement of such filing and the managing Underwriter or Underwriters, if
applicable, and shall further notify such holders and such managing Underwriter or Underwriters and, if requested, confirm such advice in writing, in all events as soon as reasonably practical after the occurrence of any of the following:
(i) when such Registration Statement becomes effective; (ii) when any post-effective amendment to such Registration Statement becomes effective; (iii) the issuance or threatened issuance by the Commission of any stop order (and the
Company shall use best efforts to take all actions required to prevent the entry of such stop order or to remove it if entered); (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or
exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any proceeding for such purpose; (v) of the occurrence or existence of any pending corporate development with
respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus (provided that
any and all of such information shall remain confidential to each holder until such information otherwise becomes public, unless disclosure by a holder is required by law; provided, further, that notwithstanding each holder’s agreement to keep
such information confidential, each such holder makes no acknowledgement that any such information is material, non-public information); and (vi) any request by the Commission for any amendment or supplement to such Registration Statement or
any Prospectus relating thereto or for additional information or of the occurrence of an event requiring the preparation of a supplement or amendment to such Prospectus so that, as thereafter delivered to the purchasers of the securities covered by
such Registration Statement, such Prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and promptly make
available to the holders of Registrable Securities included in such Registration Statement any such supplement or amendment; except that before filing with the Commission a Registration Statement or Prospectus or any amendment or supplement thereto,
including documents incorporated by reference, except in the case of registration under Section 2.2; the Company shall furnish to the holders of Registrable Securities included in such Registration Statement and to the legal counsel for any
such holders, copies of all such documents proposed to be filed sufficiently in advance of filing to provide such holders and legal counsel with a reasonable opportunity to review such documents and comment thereon, and the Company shall not file
any Registration Statement or Prospectus or amendment or supplement thereto, including documents incorporated by reference, to which such holders or their legal counsel shall reasonably object. 
 3.1.5. State Securities Laws Compliance. The Company, on or prior to the date on which the applicable Registration Statement is declared
effective, shall use its best efforts to (i) register or qualify the Registrable Securities covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions in the United States as the holders of
Registrable Securities included in such Registration Statement (in light of their intended plan of distribution) or Underwriter, if any, or their respective counsel may reasonably request in writing and (ii) take such action necessary to cause
such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may be necessary by virtue of the business and operations of the Company and do any and all other acts and
things that may be necessary or advisable to enable the holders of Registrable Securities included in such Registration Statement to consummate the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company
shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this paragraph or subject itself to taxation in any such jurisdiction. 
 3.1.6. Cooperation. The principal executive officer of the Company, the principal financial officer of the Company, the principal accounting
officer of the Company, and all other officers and members of the management of the Company shall cooperate fully in any offering of Registrable Securities hereunder, which cooperation shall include, without limitation, the preparation of the
Registration Statement with respect to such offering and all other offering materials and related documents, and participation in meetings with Underwriters, attorneys, accountants and potential Stockholders. 

 3.1.7. Records. The Company shall make available for inspection by the holders of Registrable
Securities included in such Registration Statement, any Underwriter participating in any disposition pursuant to such Registration Statement and any attorney, accountant, or other professional retained by any holder of Registrable Securities
included in such Registration Statement or any Underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause all of the Company’s officers, directors, and employees and the independent
public accountants who have certified its financial statements to make themselves available to discuss the business of the Company and to supply all information reasonably requested by any such holder, Underwriter, attorney, accountant or agent in
connection with such Registration Statement as shall be necessary to enable them to exercise their due diligence responsibility, and cause the Company’s officers, directors, and employees to supply all information requested by any of them in
connection with such Registration Statement. 
 3.1.8. Opinions and Comfort Letters. The Company shall furnish to each holder of
Registrable Securities included in any Registration Statement a signed counterpart, addressed to such holder, of (i) any opinion of counsel to the Company delivered to any Underwriter dated the effective date of the Registration Statement or,
in the event of an Underwritten Offering, the date of the closing under the applicable underwriting agreement, in customary form, scope, and substance, at a minimum to the effect that the Registration Statement has been declared effective and that
no stop order is in effect, which counsel and opinions shall be reasonably satisfactory to a majority of the holders and Underwriter or Underwriters, if any, and their respective counsel and (ii) any comfort letter from the Company’s
independent public accountants delivered to any Underwriter in customary form and covering such matters of the type customarily covered by comfort letters as the managing Underwriter or Underwriters reasonably request. In the event no legal opinion
is delivered to any Underwriter, the Company shall furnish to each holder of Registrable Securities included in such Registration Statement, at any time that such holder elects to use a Prospectus, an opinion of counsel to the Company to the effect
that the Registration Statement containing such Prospectus has been declared effective and that no stop order is in effect. 
 3.1.9.
Earnings Statement. The Company shall comply with all applicable rules and regulations of the Commission and the Securities Act, and make available to its stockholders, as soon as reasonably practicable but not later than fifteen
(15) months after the effective date of the Registration Statement, an earnings statement which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder. 
 3.1.10. Listing. The Company shall use its best efforts to cause all Registrable Securities included in any registration to be listed on such
exchanges or otherwise designated for trading in the same manner as similar securities issued by the Company are then listed or designated or, if no such similar securities are then listed or designated, in a manner satisfactory to the holders of a
majority-in-interest of the Registrable Securities included in such registration and on each inter-dealer quotation system on which any of the Company’s securities are then quoted. 
 3.1.11. Withdrawal of Stop Order. The Company shall make every reasonable effort to prevent or obtain at the earliest possible moment the
withdrawal of any stop order with respect to the applicable Registration Statement or other order suspending the use of any preliminary or final Prospectus. 
 3.1.12. CUSIP Number. The Company shall, not later than the effective date of the applicable Registration Statement, provide a CUSIP number for all Registrable Securities and provide the applicable transfer
agent with printed certificates for the Registrable Securities which certificates shall be in a form eligible for deposit with The Depository Trust Company. 
 3.1.13. FINRA. The Company shall cooperate with each holder of Registrable Securities and each Underwriter or agent, if any, participating in the disposition of such Registrable Securities and their respective
counsel in connection with any filings required to be made with the Financial Industry Regulatory Authority. 
 3.1.14. Transfer
Agent. The Company shall provide and cause to be maintained a transfer agent and registrar for all Registrable Securities covered by the applicable Registration Statement from and after a date not later than the effective date of such
Registration Statement. 
 3.1.15. Road Show. The Company shall, in the case of an Underwritten Offering, cause senior executive
officers of the Company to participate in customary “road show” presentations that may be reasonably 

 
requested by the managing Underwriter in any such Underwritten Offering and otherwise to facilitate, cooperate with, and participate in each proposed
offering contemplated herein and customary selling efforts related thereto 
 3.1.16. Additional Registration Statements. If during
the Effectiveness Period relating to the Registration Statement filed pursuant to Section 2.3, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement,
then the Company shall file as soon as reasonably practicable, but in any case prior to the applicable Filing Date, an additional Registration Statement pursuant to Section 2.3 covering the resale by the holders of Registrable Securities of not
less than the number of such Registrable Securities. 
 3.2. Underwritten Offerings. 
 3.2.1. Underwriting Agreements. If requested by the Underwriters for any Underwritten Offering requested by holders pursuant to Section 2.1,
the Company and the holders of Registrable Securities to be included therein shall enter into an underwriting agreement with such Underwriters, such agreement to be reasonably satisfactory in substance and form to the Company, the holders of a
majority-in-interest of the Registrable Securities to be included in such Underwritten Offering and the Underwriters, and to contain such terms and conditions as are generally prevailing in agreements of that type. The holders of any Registrable
Securities to be included in any Underwritten Offering pursuant to Section 2.2 shall enter into such an underwriting agreement at the request of the Company. All of the representations and warranties and the other agreements by and on the part
of the Company to and for the benefit of the Underwriters included in any such underwriting agreement shall also be made to and for the benefit of such holders, and any or all of the conditions precedent to the obligations of the Underwriters under
such underwriting agreement shall be conditions precedent to the obligations of such holders. No holder shall be required in any such underwriting agreement to make any representations or warranties to or agreements with the Company or the
Underwriters other than representations, warranties or agreements regarding such holder, such holder’s Registrable Securities, such holder’s intended method of distribution and any other representations required by law. 
 3.2.2. Price and Underwriting Discounts. In the case of an Underwritten Offering requested by holders pursuant to Section 2.1, the price,
underwriting discount and other financial terms of the related underwriting agreement for the Registrable Securities shall be determined by the holders of a majority-in-interest of the Registrable Securities. In the case of any Underwritten Offering
pursuant to Section 2.2, such price, discount and other terms shall be determined by the Company, subject to the right of the holders to withdraw their request to participate in the registration pursuant to Section 2.2 after being advised
of such price, discount and other terms. 
 3.2.3. Participation in Underwritten Offerings. No Person may participate in an
Underwritten Offering unless such Person (i) agrees to sell such Person’s securities on the basis provided in the underwriting arrangements approved by the Persons entitled to approve such arrangements and (ii) completes and executes
all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents required under the terms of such underwriting arrangements in accordance herewith. 
 3.3. Obligation to Suspend Distribution. Upon receipt of any notice from the Company of the happening of any event of the kind described in
Section 3.1.4(iii) through 3.1.4(vi), and/or, in the case of a resale registration on Form S-3 pursuant to Section 2.3 hereof, upon any suspension by the Company, pursuant to a written insider trading compliance program adopted by the
Company’s board of directors, of the ability of all “insiders” covered by such program to transact in the Company’s securities because of the existence of material non-public information, such holder of Registrable Securities
included in any Registration Statement shall immediately discontinue disposition of such Registrable Securities pursuant to the Registration Statement covering such Registrable Securities in the case of Section 3.1.4(vi) until such holder
receives the supplemented or amended Prospectus contemplated by Section 3.1.4(vi) and/or with respect to resale holders, the restriction on the ability of “insiders” to transact in the Company’s securities is removed, as
applicable, or in any case until the holder is advised in writing by the Company that the use of the Prospectus may be resumed, and receives copies of any additional or supplemental filings that are incorporated by reference in the Prospectus. In
the event that the Company shall give any such notice, the period during which the applicable Registration Statement is required to be maintained effective shall be extended by the number of days during the period from and including the date of the
giving of such notice to and including the date when each holder of Registrable Securities covered by such Registration Statement either receives the copies of the 

 
supplemented or amended Prospectus contemplated by Section 3.1.4(vi) or is advised in writing by the Company that the use of the Prospectus may be
resumed. 
 3.4. Registration Expenses. The Company shall bear all costs and expenses incurred in connection with any Demand
Registration pursuant to Section 2.1, any Piggy-Back Registration pursuant to Section 2.2, and any registration on Form S-3 effected pursuant to Section 2.3, and all expenses incurred in performing or complying with its other
obligations under this Agreement, including, without limitation: (i) all registration and filing fees and any other fees and expenses associated with filings required to be made with the SEC; (ii) fees and expenses of compliance with
securities or “blue sky” laws (including fees and disbursements of counsel in connection with blue sky qualifications of the Registrable Securities); (iii) printing expenses, duplicating, word processing, messenger, telephone,
facsimile and delivery expenses (including expenses of printing certificates for the Registrable Securities in a form eligible for deposit with The Depository Trust Company and of printing Prospectuses); (iv) the Company’s internal
expenses (including, without limitation, all salaries and expenses of its officers and employees); (v) the fees and expenses incurred in connection with the listing of the Registrable Securities as required by Section 3.1.10;
(vi) Financial Industry Regulatory Authority fees; (vii) fees and disbursements of counsel for the Company and fees and expenses for independent certified public accountants retained by the Company (including the expenses or costs
associated with the delivery of any opinions or comfort letters requested pursuant to Section 3.1.8); (viii) the reasonable fees and disbursements of any special experts retained by the Company in connection with such registration;
(ix) the reasonable fees and expenses of two (2) legal counsels, one (1) selected by the holders of a majority-in-interest of the Shares and one (1) selected by the holders of a majority-in-interest of the Founder Shares, each as
included in such registration; and (x) Securities Act liability insurance if the Company so desires. The Company shall have no obligation to pay any other costs or expenses in the course of the transactions contemplated hereby, including
underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling commissions shall be borne by such holders. Additionally, in an Underwritten
Offering, all selling stockholders and the Company shall bear the expenses of the Underwriter pro rata in proportion to the respective amount of shares each is selling in such offering. 
 3.5. Information. The holders of Registrable Securities shall provide such information as may reasonably be requested by the Company, or the
managing Underwriter, if any, in connection with the preparation of any Registration Statement, including amendments and supplements thereto, in order to effect the registration of any Registrable Securities under the Securities Act pursuant to
Section 2 and in connection with the Company’s obligation to comply with federal and applicable state securities laws. The Company shall have the right to exclude any holder that does not comply with the preceding sentence from the
applicable registration. 
 4. INDEMNIFICATION AND CONTRIBUTION. 
 4.1. Indemnification by the Company. The Company agrees to indemnify and hold harmless to the extent permitted by law each Stockholder and each other holder of Registrable Securities, and each of their
respective officers, employees, affiliates, directors, partners, members, attorneys, and agents, and each Person, if any, who controls an Stockholder and each other holder of Registrable Securities (within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act) (each, an “Stockholder Indemnified Party”), to the fullest extent permitted by applicable law from and against any expenses (including reasonable costs of investigation
and legal expenses), losses, claims, judgments, damages, or liabilities (or actions or proceedings in respect thereof, whether or not such indemnified party is a party thereto), whether joint or several, arising out of or based upon (1) any
untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary Prospectus, final Prospectus, or
summary Prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or alleged omission) to state a material fact required to be stated therein or
necessary to make the statements therein not misleading or (2) any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the
performance of its obligations under this Agreement; provided, however, that the Company will not be liable in any such case to the extent and only to the extent that any such expense, loss, claim, damage, or liability arises out of or is based upon
any untrue statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary Prospectus, final Prospectus, or summary Prospectus, or any such amendment or supplement, in reliance upon and in
conformity with information furnished to the Company, in writing, by such selling holder expressly for use therein. The Company 

 
also shall indemnify any Underwriter of the Registrable Securities, their officers, affiliates, directors, partners, members, and agents on substantially the
same basis as that of the indemnification provided above in this Section 4.1. The Company shall notify the holders promptly of the institution, threat or assertion of any proceeding arising from or in connection with the transactions
contemplated by this Agreement of which the Company is aware. 
 4.2. Indemnification by Holders of Registrable Securities. Each
selling holder of Registrable Securities will severally and not jointly, in the event that any registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling holder, indemnify
and hold harmless to the fullest extent permitted by applicable law the Company, each of its directors, officers, employees, and agents and each Person who controls the Company within the meaning of the Securities Act, against any losses, claims,
judgments, damages, liabilities, or expenses (including reasonable costs of investigation and legal expenses) whether joint or several, insofar as such losses, claims, damages, liabilities, or expenses (or actions or proceedings in respect thereof,
whether or not such indemnified party is a party thereto) arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement under which the sale of such Registrable
Securities was registered under the Securities Act, any preliminary Prospectus, final Prospectus, or summary Prospectus contained in the Registration Statement, or any amendment or supplement to the Registration Statement, or arise out of or are
based upon any omission or the alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading to the extent and only to the extent that the statement or omission was made in reliance
upon and in conformity with information furnished in writing to the Company by such selling holder expressly for use therein, and shall reimburse the Company, its directors and officers, and each other selling holder or controlling Person for any
legal or other expenses reasonably incurred by any of them in connection with investigation or defending any such loss, claim, damage, liability or action. Each selling holder’s indemnification obligations hereunder shall be several and not
joint and shall be limited to the amount of any net proceeds actually received by such selling holder upon the sale of the Registrable Securities giving rise to such indemnification obligation. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of the Company or any indemnified party. 
 4.3. Conduct of Indemnification
Proceedings. Promptly after receipt by any Person of any notice of any loss, claim, damage, or liability or any action in respect of which indemnity may be sought pursuant to Section 4.1 or 4.2, such Person (the “Indemnified
Party”) shall, if a claim in respect thereof is to be made against any other Person for indemnification hereunder, notify such other Person (the “Indemnifying Party”) in writing of the loss, claim, judgment,
damage, liability, or action; provided, however, that the failure by the Indemnified Party to notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which the Indemnifying Party may have to such Indemnified Party
hereunder, except and solely to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party. If
the Indemnified Party is seeking indemnification with respect to any claim or action brought against the Indemnified Party, then the Indemnifying Party shall be entitled to participate in such claim or action and, to the extent that it wishes,
jointly with all other Indemnifying Parties, to assume control of the defense thereof with counsel satisfactory to the Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the
defense of such claim or action, the Indemnifying Party shall not be liable to the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of
investigation; provided, however, that in any action in which both the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall have the right to employ separate counsel (but no more than one such separate
counsel) to represent the Indemnified Party and its controlling Persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party, with the fees and
expenses of such counsel to be paid by the Indemnifying Party based upon the written opinion of counsel of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them (in which case, if the Indemnified Party notifies the Indemnifying Party in writing that such Indemnified Party elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have
the right to assume the defense of such claim on behalf of such Indemnified Party). If such defense is not assumed by the Indemnifying Party, the Indemnifying Party will not be subject to any liability for any settlement made without its consent,
but such consent may not be unreasonably withheld, conditioned or delayed; provided, however, that an Indemnifying Party shall not be required to consent to any settlement involving the imposition of equitable remedies or involving the imposition of
any material obligations on such Indemnifying Party other than financial obligations for which such Indemnified Party will be indemnified 

 
hereunder. If the Indemnifying Party assumes the defense, the Indemnifying Party shall have the right to settle such action without the consent of the
Indemnified Party; provided, however, that the Indemnifying Party shall be required to obtain such consent (which consent shall not be unreasonably withheld, conditioned or delayed) if the settlement includes any admission of wrongdoing on the part
of the Indemnified Party or any restriction on the Indemnified Party or its officers or directors. No Indemnifying Party shall consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the
giving by the claimant or plaintiff to each Indemnified Party of an unconditional release from all liability in respect to such claim or litigation. The Indemnifying Party or Parties shall not, in connection with any proceeding or related
proceedings, be liable for the reasonable fees, disbursements and other charges of more than one separate firm at any one time for all such Indemnified Party or Parties unless (x) the employment of more than one counsel has been authorized in
writing by the Indemnifying Party or parties, (y) a conflict or potential conflict exists or may exist (based on advice of counsel to an Indemnified Party) between such Indemnified Party and the other Indemnified Parties or (z) based on
advice of counsel, an Indemnified Party has reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the other Indemnified Parties, in each of which cases the Indemnifying
Party shall be obligated to pay the reasonable fees and expenses of such additional counsel or counsels. Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the
extent incurred in connection with investigating or preparing to defend such proceeding in a manner not inconsistent with this Section 4.3) shall be paid to the Indemnified Party, as incurred, within ten trading days of written notice thereof
to the Indemnifying Party; provided, that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is judicially determined to be not
entitled to indemnification hereunder. 
 4.4. Contribution. 
 4.4.1. If the indemnification provided for in the foregoing Sections 4.1, 4.2 and 4.3 is unavailable to any Indemnified Party or insufficient to hold it
harmless in respect of any loss, claim, damage, liability, or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a
result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in connection with the actions or omissions which resulted in such
loss, claim, damage, liability, or action, as well as any other relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. 
 4.4.2. The parties hereto agree that it would not be just
and equitable if contribution pursuant to this Section 4.4 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately preceding
Section 4.4.1. The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage, liability or action referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses incurred by such Indemnified Party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 4.4, no holder of Registrable Securities shall be
required to contribute any amount in excess of the dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received by such holder from the sale of Registrable Securities which gave rise
to such contribution obligation. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation. If indemnification is available under this Section 4, the Indemnifying Parties shall indemnify each Indemnified Party to the full extent provided in Sections 4.1 and 4.2 hereof without regard to the relative fault of said
Indemnifying Parties or Indemnified Party. 
 5. REPORTS UNDER THE SECURITIES ACT AND EXCHANGE ACT. 
 5.1. The Company covenants that it shall file any reports required to be filed by it under the Securities Act and the Exchange Act and shall take such
further action as the holders of Registrable Securities may reasonably request, all to the extent required from time to time to enable such holders to sell Registrable Securities without registration 

 
under the Securities Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such Rules may be amended from time to
time, or any similar Rule or regulation hereafter adopted by the Commission. 
 6. NO INCONSISTENT AGREEMENTS; ADDITIONAL RIGHTS; EXISTING
AGREEMENT. 
 6.1. Except with respect to Allowable Registration Statements, the Company has not entered, as of the date hereof, nor
shall the Company, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have the effect of impairing the rights granted to the Stockholders in this Agreement or otherwise conflict with the
provisions hereof. The Company has not previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in full. Neither the Company nor any of its security
holders (other than the Stockholders (or their successors or permitted assigns) in such capacity pursuant hereto) may include securities of the Company in any Registration Statement filed pursuant to Section 2.3 other than the Registrable
Securities. Except with respect to Allowable Registration Statements, and unless the Company receives the consent of each of (i) the holders of a majority-in-interest of the Shares held by the Stockholders or the Permitted Transferees of such
Stockholders and (ii) the holders of a majority-in-interest of the Founder Shares held by the Stockholders or the Permitted Transferees of such Stockholders, the Company shall not file any other Registration Statements until all Registrable
Securities are registered pursuant to a Registration Statement that is declared effective by the Commission. 
 7. MISCELLANEOUS. 

7.1. Term. This Agreement shall terminate upon earlier of (a) the fifth anniversary of the date of this Agreement or (b) the date as
of which (i) all of the Registrable Securities have been sold pursuant to a Registration Statement (but in no event prior to the applicable period referred to in Section 4(3) of the Securities Act and Rule 174 thereunder) or (ii) the
holders are permitted to sell their Registrable Securities under Rule 144(k) under the Securities Act (or any similar provision then in force permitting the sale of restricted securities without limitation on the amount of securities sold or the
manner of sale). The provisions of Section 4 and Section 5 shall survive any termination. 
 7.2. Assignment; No Third
Party Beneficiaries. The registration rights of any holder under this Agreement with respect to any Registrable Securities may be transferred and assigned, provided, however, that no such transfer or assignment shall be
binding upon or obligate the Company to any such assignee unless and until the Company shall have received written notice of such transfer or assignment as herein provided and a written agreement of the assignee to be bound by the provisions of this
Agreement. Any transfer or assignment made other than as provided in the first sentence of this Section 7.2 shall be null and void. This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the
parties and the permitted assigns of the Stockholder or holder of Registrable Securities or of any assignee of the Stockholder or holder of Registrable Securities. This Agreement is not intended to confer any rights or benefits on any Persons that
are not party hereto other than as expressly set forth in Article 4 and this Section 7.2. The Company may not assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the holders of the then
outstanding Registrable Securities. 
 7.3. Notices. All notices, demands, requests, consents, approvals or other
communications (collectively, “Notices”) required or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be either Personally served, delivered by reputable air
courier service with charges prepaid guaranteeing overnight delivery, or transmitted by hand delivery, telegram, electronic mail, telex, facsimile, or by mailing in the same sealed envelope, or registered first-class mail, postage prepaid, return
receipt requested addressed as set forth below, or to such other address as such party shall have specified most recently by written notice. Notice shall be deemed given (i) on the date of delivery if Personally served, (ii) when receipt
is acknowledged in writing by addressee, if transmitted by telegram, electronic mail, telex or facsimile, provided, that if such service or transmission is not on a business day or is after normal business hours, then such notice shall be deemed
given on the next business day, and (iii) five (5) business days after having been deposited in the mail, postage prepaid, if mailed by first-class mail. Notice otherwise sent as provided herein shall be deemed given on the next business
day following timely delivery of such notice to a reputable air courier service with an order for next-day delivery, provided, however, that notice of a change in address shall be effective only upon receipt. 
 If to any holder of Shares or Founder Shares to such addresses on the signature pages hereto. 

 with respect to a holder of Shares, with a copy to (but which shall not constitute notice to such holder of Shares):

 Paul, Hastings, Janofsky & Walker LLP 
 515 S. Flower
St., Floor 25 
 Los Angeles, California 90071 
 Attention: Robert R. Carlson, Esq. 
 Facsimile: (213) 996-3220 
 with respect to a holder of Founder Shares, with a copy to (but which shall not constitute notice to such holder of Founder Shares): 
 Ellenoff Grossman & Schole, LLP 
 150 East 42nd Street 
 New York, New York 10017 
 Attention: Douglas Ellenoff, Esq. 
 Facsimile: (212) 370-7889 
 If to the Company to: 
 Great American Group, Inc. 
 21860 Burbank Blvd. 
 Suite 300 South 
 Woodland Hills, CA 91367 
 Attention: Andrew Gumaer 
 Facsimile: (818) 884-2976 
 with a copy to (but which shall not constitute notice to the Company): 
 Paul, Hastings, Janofsky & Walker LLP 
 515 S. Flower St., Floor 25 
 Los Angeles, California 90071 
 Attention: Robert R. Carlson, Esq. 
 Facsimile: (213) 996-3220 
 7.4. Severability.
This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any
such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible that is valid and
enforceable. 
 7.5. Counterparts. This Agreement may be executed in multiple counterparts, including by facsimile or other electronic
means, each of which shall be deemed an original, and all of which taken together shall constitute one and the same instrument. 
 7.6.
Entire Agreement. This Agreement (including all agreements entered into pursuant hereto and all certificates and instruments delivered pursuant hereto and thereto) constitute the entire agreement of the parties with respect to the subject
matter hereof and supersede all prior and contemporaneous agreements, representations, understandings, negotiations and discussions between the parties, whether oral or written. 
 7.7. Modifications and Amendments. No amendment, modification or termination of this Agreement shall be binding upon any party unless executed in
writing by such party and signed by the Company and the holders of a majority of Registrable Securities then outstanding. Each holder of any Registrable Securities at the time or thereafter outstanding shall be bound by any amendment, modification,
waiver or consent authorized by this Section 7.7 whether or not such Registrable Securities shall have been marked accordingly. 

 7.8. Titles and Headings. Titles and headings of sections of this Agreement are for convenience
only and shall not affect the construction of any provision of this Agreement. 
 7.9. Waivers and Extensions. Any party to this
Agreement may waive any right, breach or default which such party has the right to waive, provided that such waiver will not be effective against the waiving party unless it is in writing, is signed by such party, and specifically refers to this
Agreement. Waivers may be made in advance or after the right waived has arisen or the breach or default waived has occurred. Any waiver may be conditional. No waiver of any breach of any agreement or provision herein contained shall be deemed a
waiver of any preceding or succeeding breach thereof nor of any other agreement or provision herein contained. No waiver or extension of time for performance of any obligations or acts shall be deemed a waiver or extension of the time for
performance of any other obligations or acts. Except as otherwise expressly provided herein, no failure on the part of any party to exercise, and no delay in exercising, any right, power or remedy hereunder, or otherwise available in respect hereof
at law or in equity, shall operate as a waiver thereof, nor shall any single or partial exercise of such right, power or remedy by such party preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.

 7.10. Remedies. In the event of a breach by the Company or by an Stockholder of any of their respective obligations under this
Agreement, each Stockholder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights
under this Agreement. The Company and each Stockholder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that,
in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate. 
 7.11. Independent Nature of Holders’ Obligations and Rights. The obligations of each holder hereunder are several and not joint with the obligations of any other holder hereunder, and no holder shall be
responsible in any way for the performance of the obligations of any other holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any holder pursuant hereto or thereto, shall
be deemed to constitute the holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the holders are in any way acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other holder to be joined as an additional
party in any proceeding for such purpose. 
 7.12. Governing Law. 
 (a) This Agreement shall be governed by, interpreted under, and construed in accordance with the internal laws of the State of Delaware applicable to agreements made and to be performed within the State of Delaware,
without giving effect to any choice-of-law provisions thereof that would compel the application of the substantive laws of any other jurisdiction. 
 (b) To the fullest extent permitted by applicable law, each party hereto (i) agrees that any claim, action or proceeding by such party seeking any relief whatsoever arising out of, or in connection with, this Agreement or the
transactions contemplated hereby shall be brought only in any Federal court located in Delaware and in any Delaware State court (such venue as determined by the claimant party hereto) and not in any other State or Federal court in the United States
of America or any court in any other country, (ii) agrees to submit to the exclusive jurisdiction of such courts located in the State of Delaware for purposes of all legal proceedings arising out of, or in connection with, this Agreement or the
transactions contemplated hereby, and (iii) irrevocably waives any objection which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such proceeding brought in such a
court has been brought in an inconvenient forum. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

 IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be executed and
delivered by their duly authorized representatives as of the date first written above. 
  

	
	 COMPANY
  
 GREAT AMERICAN GROUP, INC.

	
	 By:_______________________________
 Name:
 Title:

	
	  
 STOCKHOLDERS:

	
	 __________________________________
 Harvey
Yellen
 Address for Notice:

	
	
	 __________________________________
 Andrew
Gumaer
 Address for Notice:

	
	
	 __________________________________
 Scott Carpenter
 Address for Notice:

	
	
	 __________________________________
 Paul Erickson
 Address for Notice:

	
	
	 __________________________________
 Lester Friedman
 Address for Notice:

	
	
	 __________________________________
 Tom Pabst
 Address for Notice:

 [Signature Page to Registration Rights Agreement] 

	
	
	 __________________________________
 Mark Weitz

Address for Notice:

	
	
	 __________________________________
 Brian
Yellen
 Address for Notice:

	
	
	 __________________________________
 Hanover Overseas Limited
 Address for Notice:

	
	
	 __________________________________
 STC Investment Holdings LLC
 Address for Notice:

	
	
	 __________________________________
 Solar Capital, LLC
 Address for Notice:

	
	
	 __________________________________
 Jakal Investments LLC
 Address for Notice:

	
	
	 __________________________________
 Mark Klein
 Address for Notice:

	
	
	 __________________________________
 David Hawkins
 Address for Notice:

	
	
	 __________________________________
 Steven Shenfeld
 Address for Notice:

 [Signature Page to Registration Rights Agreement] 

	
	
	 __________________________________
 Bradford
Peck
 Address for Notice:

	
	
	 __________________________________
 Frederick Kraegel

 Address for Notice:

 SCHEDULE I 
  

									
	 Stockholder
	 	 Closing Shares
	 	 Contingent Shares
	 	 Founder Shares
	 	 All Shares

					
	 Harvey Yellen
	 	5,280,000	 	2,640,000	 		 	7,920,000
					
	 Andrew Gumaer
	 	5,280,000	 	2,640,000	 		 	7,920,000
					
	 Scott Carpenter
	 	273,727	 	129,107	 		 	402,834
					
	 Paul Erickson
	 	270,795	 	128,507	 		 	399,302
					
	 Lester Friedman
	 	247,332	 	123,703	 		 	371,035
					
	 Tom Pabst
	 	268,839	 	128,507	 		 	397,346
					
	 Mark Weitz
	 	289,368	 	150,126	 		 	439,494
					
	 Brian Yellen
	 	89,939	 	60,050	 		 	149,989
	Hanover Overseas Limited	 		 		 	1,125,000	 	 1,125,000

	STC Investment Holdings LLC	 		 		 	 1,500,000
	 	 1,500,000

	 Solar Capital, LLC
	 		 		 	 500,000
	 	 500,000

					
	 Jakal Investments LLC
	 		 		 	 380,000
	 	 380,000

					
	 Mark Klein
	 		 		 	 375,000
	 	 375,000

					
	 David Hawkins
	 		 		 	 20,000
	 	 20,000

					
	 Steven Shenfeld
	 		 		 	 60,000
	 	 60,000

					
	 Bradford Peck
	 		 		 	 20,000
	 	 20,000

					
	 Frederick Kraegel
	 		 		 	 20,000
	 	 20,000

					
	 Total
	 	12,000,000	 	6,000,000	 	4,000,000	 	22,000,000Asset Purchase Agreement

 Exhibit 4.11 
 Asset Purchase Agreement 
 This Agreement is entered into 
 by and between 
 F. Hoffmann-La Roche Ltd 
 with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“ROCHE Basel”) 
 and 
 Hoffmann-La Roche Inc. 
 with an office and place of business at 340 Kingsland Street, Nutley, New Jersey 07110, U.S.A. (“ROCHE Nutley”; ROCHE Basel and ROCHE Nutley together referred to as “ROCHE”) 
 on the one hand 
 and 
 Evotec Neurosciences GmbH 
 with their office and place of business at
Schnackenburgallee 114, 22525 Hamburg, Germany (“EVOTEC”) 
 on the other hand 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 WHEREAS, ROCHE and EVOTEC entered into a License Agreement effective as of December 19, 2003, as
amended on April 15, 2004 (“2003-Agreement”), under which ROCHE granted EVOTEC certain rights and licenses to patent rights and know-how; 
 WHEREAS, the 2003-Agreement has been replaced and superseded by the Amended and Restated License Agreement (“License Agreement”) signed on March 4, 2009 and effective retroactively, as of
December 19, 2003. 
 WHEREAS, EVOTEC wishes to return to ROCHE all rights and licenses previously granted by ROCHE to it under the
License Agreement and to sell to ROCHE certain patents and know-how owned by EVOTEC as set forth herein; 
 NOW, THEREFORE, the Parties
hereby agree as follows: 
  

 2 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 Asset Purchase Agreement 
  

							
	1.	  	 Definitions
	  	6
		  	1.1	  	Affiliate	  	6
		  	1.2	  	Agreement	  	6
		  	1.3	  	Assets	  	6
		  	1.4	  	Business Day	  	6
		  	1.5	  	Calendar Quarter	  	6
		  	1.6	  	Calendar Year	  	7
		  	1.7	  	Commercially Reasonable Efforts	  	7
		  	1.8	  	Combination Product	  	7
		  	1.9	  	Condition Precedent	  	7
		  	1.10	  	Compounds	  	7
		  	1.11	  	Control	  	7
		  	1.12	  	Confidential Information	  	8
		  	1.13	  	Cover	  	8
		  	1.14	  	EVOTEC Know-How	  	8
		  	1.15	  	EVOTEC Patent Rights	  	8
		  	1.16	  	EVT 101	  	9
		  	1.17	  	EVT 103	  	9
		  	1.18	  	Expert	  	9
		  	1.19	  	FDA	  	9
		  	1.20	  	FDCA	  	9
		  	1.21	  	Field	  	9
		  	1.22	  	Filing	  	9
		  	1.23	  	First Commercial Sale	  	9
		  	1.24	  	IND	  	9
		  	1.25	  	Initiation	  	9
		  	1.26	  	Invention	  	10
		  	1.27	  	Joint Know-How	  	10
		  	1.28	  	Joint Patent Rights	  	10
		  	1.29	  	Know-How	  	10
		  	1.30	  	Material Adverse Change	  	10
		  	1.31	  	NDA	  	10
		  	1.32	  	Net Sales	  	10
		  	1.33	  	Party	  	11
		  	1.34	  	Payment Term	  	11
		  	1.35	  	Patent Rights	  	11
		  	1.36	  	Phase II Study	  	11
		  	1.37	  	Phase III Study	  	12
		  	1.38	  	[***]	  	12
		  	1.39	  	Product	  	12
		  	1.40	  	Regulatory Authority	  	12
		  	1.41	  	Regulatory Approval	  	12
		  	1.42	  	ROCHE Group	  	12
		  	1.43	  	ROCHE Know-How	  	12
		  	1.44	  	ROCHE Patent Rights	  	12
		  	1.45	  	ROCHE Base Patent Rights	  	12

  

 3 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

							
		  	1.46	  	Licensee	  	13
		  	1.47	  	Summary Report	  	13
		  	1.48	  	Territory	  	13
		  	1.49	  	Third Party	  	13
		  	1.50	  	Transaction	  	13
		  	1.51	  	US	  	13
		  	1.52	  	VAT	  	13
	2.	  	 Sale and Purchase
	  	13
	3.	  	 Signing Date, Closing Date and Closing
	  	14
		  	3.1	  	Signing Date	  	14
		  	3.2	  	Closing Date	  	14
		  	3.3	  	Closing	  	14
	4.	  	 Conditions to Closing, Covenants between Signing and Closing
	  	15
		  	4.1	  	Conditions to the Parties’ Obligations	  	15
		  	4.2	  	No Refusal or Delay	  	15
		  	4.3	  	Conduct of Business and Other	  	15
	5.	  	 EVOTEC’s Post Closing Obligations
	  	15
		  	5.1	  	Cooperation	  	15
		  	5.2	  	Disclosure of Know-How and Information	  	16
		  	5.3	  	Transfer of Regulatory Documents	  	16
		  	5.4	  	Ongoing Studies	  	16
		  	5.5	  	Pharmacoviligance	  	17
		  	5.6	  	Point of Contact	  	17
	6.	  	 Manufacture and Supply
	  	17
	7.	  	 Regulatory
	  	17
	8.	  	 Purchase Price
	  	18
	9.	  	 Further Payments
	  	18
		  	9.1	  	Development Event Payments	  	18
		  	9.2	  	Sales Based Events	  	18
		  	9.3	  	Commercial Payments	  	19
		  	9.4	  	Final Payment	  	20
	10.	  	 Accounting and reporting
	  	20
		  	10.1	  	Timing of Payments	  	20
		  	10.2	  	Late Payment	  	20
		  	10.3	  	Method of Payment	  	21
		  	10.4	  	Currency Conversion	  	21
		  	10.5	  	Reporting	  	21
	11.	  	 Taxes
	  	21
	12.	  	 Auditing
	  	21
		  	12.1	  	Auditing	  	21
		  	12.2	  	Sharing of draft reports	  	22
		  	12.3	  	Over-or Underpayment	  	22
		  	12.4	  	Duration of Audit Rights	  	22
	13.	  	 Guarantees of EVOTEC
	  	22
		  	13.1	  	Incorporation of EVOTEC	  	23
		  	13.2	  	Assets	  	23
		  	13.3	  	Know-How and Intellectual Property Rights	  	23
		  	13.4	  	Litigation	  	24

  

 4 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

							
		  	13.5	  	All of NMDA program	  	24
		  	13.6	  	Taxes	  	24
		  	13.7	  	Full disclosure	  	24
		  	13.8	  	Safety Data	  	24
		  	13.9	  	Inventors	  	24
		  	13.10	  	No Claims	  	24
		  	13.11	  	No Conflict	  	25
	14.	  	 EVOTEC’s Liability And Limitations to EVOTEC’s Liabilities; indemnification with respect to employees of
EVOTEC
	  	25
		  	14.1	  	Scope of Guarantees	  	25
		  	14.2	  	Indemnification with respect to employees of EVOTEC	  	26
	15.	  	 Guarantee of ROCHE
	  	27
		  	15.1	  	Representation	  	27
		  	15.2	  	Indemnification	  	28
		  	15.3	  	Further Indemnification	  	28
		  	16.	  	Covenants of ROCHE	  	28
		  	16.1	  	Development and Commercialisation of a Product by ROCHE	  	28
		  	16.2	  	EVOTEC’s Rights to Information	  	28
		  	16.3	  	Payment	  	28
		  	16.4	  	Publications	  	29
		  	16.5	  	Failure of ROCHE to comply with Covenants under Sections 16.1, 16.2 or 16.3	  	29
	17.	  	 Transfer of Rights
	  	29
		  	17.1	  	Prior to First Commercial Sale	  	29
		  	17.2	  	Within four (4) years from First Commercial Sale	  	30
		  	17.3	  	After four (4) years from First Commercial Sale	  	30
		  	17.4	  	No further Payments	  	30
	18.	  	 Termination
	  	31
	19.	  	 Miscellaneous
	  	31
		  	19.1	  	Confidentiality	  	31
		  	19.2	  	Governing Law	  	31
		  	19.3	  	Disputes	  	31
		  	19.4	  	Arbitration	  	31
		  	19.5	  	Assignment	  	32
		  	19.6	  	Independent Contractor	  	32
		  	19.7	  	Rights of Retention and Set-off	  	32
		  	19.8	  	Expenses and Fees	  	32
		  	19.9	  	Unenforceable Provisions and Severability	  	32
		  	19.10	  	Waiver	  	32
		  	19.11	  	Appendices	  	32
		  	19.12	  	Amendments	  	33
		  	19.13	  	Notice	  	33

  

 5 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1. Definitions 
 As used in this Agreement, the following terms, whether used in the singular or plural, shall have the following meanings: 
 1.1 Affiliate 
 The term “Affiliate” shall mean: 
  

	 	a)	An entity that owns directly or indirectly, a controlling interest in a Party, by stock ownership or otherwise; 

  

	 	b)	any entity in which a Party owns a controlling interest, by stock ownership or otherwise, or; 

  

	 	c)	any entity under common control with a Party, directly or indirectly. 

 For purposes of this paragraph, “controlling interest” and “control” mean ownership of more than fifty percent (50%) of the voting stock permitted to vote for the election of the board of
directors or any other arrangement resulting in control of or the right to control the management and the affairs of the entity or Party in question. 
 For purposes of this Agreement, Genentech, Inc., 1 DNA Way, South San Francisco, 94080-4990, California, USA and Chugai Pharmaceutical Co. Ltd., 1-1 Nihonbashi-Muromachi 2-chome, Chuo-ku, Tokyo, 103-8324, Tokyo,
104-8301, Japan (“Chugai”), each shall not be deemed an Affiliate of ROCHE, unless ROCHE opts for the inclusion of Genentech or an affiliate of Genentech and/ or Chugai by giving written notice to EVOTEC. 
 1.2 Agreement 
 The term “Agreement” shall
mean this document including any and all appendices and amendments to it as may be added and/or amended from time to time in accordance with the provisions of this Agreement. 
 1.3 Assets 
 The term “Assets” shall mean (i) EVOTEC’s rights under the ROCHE
Patent Rights, the ROCHE Know-How, and Roche’s interest in the Joint Patent Rights and the Joint Know-How and (ii) (a) the EVOTEC Patent Rights, (b) the EVOTEC Know-How relating to Compounds within clause (i) of the
definition of Compound in Section 1.10 and/or Products containing such a Compound, (c) EVOTEC’s interest in the Joint Patent Rights, and (d) EVOTEC’s interest in the Joint Know-How relating to Compounds within clause
(i) of the definition of Compound in Section 1.10 and/or Products containing such a Compound. 
 1.4 Business Day 
 The term “Business Day” shall mean 9:00am to 5:00pm local time on a day other than a Saturday, Sunday or bank or other public or federal holiday
in Germany or Switzerland. 
 1.5 Calendar Quarter 
 The term “Calendar Quarter” shall mean each period of three (3) consecutive calendar months, ending March 31, June 30, September 30, and December 31. 
  

 6 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1.6 Calendar Year 
 The term “Calendar Year” shall mean the period of time beginning on January 1 and ending December 31, except for the first year which shall begin on the Closing Date and end on December 31.

 1.7 Commercially Reasonable Efforts 
 The term “Commercially Reasonable Efforts” shall mean those efforts, activities and measures, which another pharmaceutical company of comparable size as ROCHE would consider to be commercially reasonable, feasible and viable to be
performed, undertaken or made in or under the specific circumstances for its own pharmaceutical products with similar market potential, using prudent scientific and business judgment. ROCHE shall be deemed diligent as long as ROCHE, its Affiliates
or Licensees actively develop and/or commercialize at least one Product in at least one indication during the Payment Term. 
 ROCHE does not
always seek to market its own products in every country or seek to obtain regulatory approval in every country or for every potential indication. As a result, the exercise of diligence by ROCHE is to be determined by judging its efforts taken as a
whole for development and commercialization by ROCHE (its Affiliates and Licensees) of a first Product in a first indication in the Territory. 
 1.8
Combination Product 
 The term “Combination Product” shall mean a Product that, in addition to containing as active ingredient
a product which is a Product, also contains at least one other active pharmaceutical ingredient in a finished form that is not a Product. 
 1.9 Condition
Precedent 
 The term “Condition Precedent” shall mean the conditions set forth in Section 4 of this Agreement. 

1.10 Compounds 
 The term “Compounds”
shall mean (i) EVT 101 and EVT 103 and other compound structures Covered by the patent applications and patents for NMDA-2B receptor antagonists listed in Appendix 1 to this Agreement, including their salts, polymorphs, crystal forms, esters,
hydrates, solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers, and (ii) and all NMDA-2B receptor antagonists, including their salts, polymorphs, crystal forms, esters, hydrates,
solvates, chelates, clathrates, metabolites that are NMDA-2B receptor antagonists, pro-drugs, isomers and enantiomers, which are Covered by Patent Rights Controlled by EVOTEC at the Closing Date, provided however such Patent Rights or relevant
compounds did not become Controlled by EVOTEC more than six (6) months after the Signing Date as a result of a merger of EVOTEC with a Third Party, the acquisition of EVOTEC by a Third Party, the sale or other transfer involving all or
substantially all of the assets of EVOTEC to a Third Party, the acquisition of a Third Party by EVOTEC or the sale or other transfer involving all or substantially all of the assets of a Third Party to EVOTEC, or any similar transaction involving
EVOTEC and a Third Party. 
 1.11 Control 
 The term “Control” shall mean (as an adjective or as a verb including conjugations and variations such as “Controls” “Controlled” or “Controlling”) (a) with respect to Patent Rights, Inventions
and/or Know-How, the possession by a Party of the ability to grant a license or sublicense of such Patent Rights and/or Know-How 
  

 7 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 
without violating the terms of any agreement or arrangement between such Party and any other party and (b) with respect to proprietary materials, the
possession by a Party of the ability to supply such proprietary materials to the other Party as provided herein without violating the terms of any agreement or arrangement between such Party and any other party. 
 1.12 Confidential Information 
 The term
“Confidential Information” shall mean any and all information, data or know-how (including Know-How), whether technical or non-technical, oral or written, owned by or that is disclosed by one party or its Affiliates (“Disclosing
Party”) to the other party or its Affiliates (“Receiving Party”). Information shall not include any information, data or know-how which: 
  

	 	(i)	was generally available to the public at the time of disclosure, or information which becomes available to the public after disclosure by the Disclosing Party other than through
fault (whether by action or inaction) of the Receiving Party, 

  

	 	(ii)	can be shown by cogent written records to have been already known to the Receiving Party prior to its receipt from the Disclosing Party, 

  

	 	(iii)	is obtained at any time lawfully from a Third Party having no obligation of confidentiality to the Disclosing Party under circumstances permitting its use or disclosure,

  

	 	(iv)	is developed independently by the Receiving Party as evidenced by written records other than through knowledge of Confidential Information of the Disclosing Party and by persons
having no access to the Confidential Information of the Disclosing Party, 

  

	 	(v)	is required to be disclosed by the Receiving Party to comply with a court or administrative order providing the Receiving Party furnishes prompt notice (in no event less than three
(3) days) to the Disclosing Party to enable it to resist such disclosure, or (vi) is approved in writing by the Disclosing Party for release by the Receiving Party. 

 The terms of this Agreement shall be considered Confidential Information of both Parties. 
 1.13 Cover 
 The term “Cover” shall mean (as an adjective or as a verb including
conjugations and variations such as “Covered,” “Coverage” or “Covering”) that the developing, making, using, offering for sale, promoting, selling, exporting or importing of a given compound, formulation or product
would infringe a Valid Claim in the absence of a license under the Patent Rights to which such Valid Claim pertains. The determination of whether a compound, formulation, process or product is Covered by a particular Valid Claim shall be made on a
country-by-country basis. 
 1.14 EVOTEC Know-How 
 The term “EVOTEC Know-How” shall mean the Know-How that EVOTEC Controls at the Closing Date. 
 1.15 EVOTEC Patent Rights

 The term “EVOTEC Patent Rights” shall mean the Patent Rights that EVOTEC Controls, relating to or arising from the discovery,
manufacture, development or commercialization of or Covering a Compound or a Product. 
  

 8 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1.16 EVT 101 
 The term “EVT 101” shall mean [***]. 
 1.17 EVT 103 
 The term “EVT 103” shall mean [***]. 
 1.18 Expert 
 The term “Expert” shall mean a person with no less than fifteen (15) years of pharmaceutical industry experience and expertise having
occupied at least one senior position within a large pharmaceutical company relating to product marketing and/or pricing but excluding any current or former employee or consultant of either Party. Such person shall be fluent in the English language.

 1.19 FDA 
 The term “FDA”
shall mean the Food and Drug Administration of the United States of America. 
 1.20 FDCA 
 The term “FDCA” shall mean the Food, Drug and Cosmetics Act. 
 1.21 Field 
 The term “Field” shall mean the prevention, diagnosis and/or treatment of human
diseases. 
 1.22 Filing 
 The term
“Filing” shall mean the submission of an application to the FDA as defined in the FDCA and applicable regulations, or the equivalent application to the equivalent agency in any other country or group of countries, the official approval of
which is required before any lawful commercial sale or marketing of Products. 
 1.23 First Commercial Sale 
 The term “First Commercial Sale” shall mean the first invoiced sale of a Product to a Third Party by the ROCHE Group following the receipt of
any Regulatory Approval required for the sale of such Product, if any. 
 1.24 IND 
 The term “IND” shall mean an application as defined in the FDCA and applicable regulations promulgated by the FDA, or the equivalent application
to the equivalent agency in any other country or group of countries, the filing of which is necessary to commence clinical testing of the Products in humans. 
 1.25 Initiation 
 The term “Initiation” shall mean the date that a human is first dosed with the Product in a Phase
II Study or Phase III Study, as applicable, approved by the respective Regulatory Authority. 
  

 9 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1.26 Invention 
 The term “Invention” shall mean an invention that is conceived or reduced to practice in the conduct of any activity that is carried out pursuant to the License Agreement. 
 1.27 Joint Know-How 
 The term “Joint
Know-How” shall mean Know-How that is made jointly in the conduct of any activity carried out pursuant to the License Agreement jointly by employees of EVOTEC and a member of the ROCHE Group with or without a Third Party. 
 1.28 Joint Patent Rights 
 The term “Joint Patent
Rights” shall mean all Patent Rights Covering an Invention that is conceived or reduced to practice in the conduct of any activity carried out pursuant to the License Agreement jointly by employees of EVOTEC and a member of the ROCHE Group with
or without a Third Party. 
 1.29 Know-How 
 The term “Know-How” shall mean data, knowledge and information, including materials, samples, chemical manufacturing data, toxicological data, pharmacological data, preclinical data, assays, platforms, formulations,
specifications, quality control testing data, that are necessary or useful for the discovery, manufacture, development or commercialization of Compounds or Products. 
 1.30 Material Adverse Change 
 The term “Material Adverse Change” shall mean any effect or
change that would be materially adverse to the Assets taken as a whole or on the ability of EVOTEC to consummate timely the Transaction. 
 1.31 NDA 

 The term “NDA” shall mean a new drug application, including all necessary documents, data, and other information concerning a
Product, required for Regulatory Approval of the Product as a pharmaceutical product by the FDA or an equivalent application to the equivalent agency in any other country or group of countries (e.g. the marketing authorization application (MAA) in
the EU). 
 1.32 Net Sales 
 The term
“Net Sales” shall mean the amount calculated by subtracting from the amount of Adjusted Gross Sales (as defined below) a lump sum deduction of five percent 5%) of Adjusted Gross Sales in lieu of those sales-related deductions which are not
accounted for by the ROCHE Group on a product-by-product basis (e.g. outward freights, postage charges, transportation insurance, packaging materials for dispatch of goods, custom duties, bad debt expense); 
 For purposes of this definition of “Net Sales”, “Adjusted Gross Sales” shall mean the amount of gross sales of the Product invoiced
by the ROCHE Group to Third Parties less deductions such as: 
  

	 	a)	Governmental price reductions and changes to reserves of governmental price reductions, such as price reductions, rebates to managed care organizations or social and welfare
systems, charge backs or 

  

 10 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

	 	 
reserves for chargebacks, cash sales incentives (but only to the extent it is a sales related deduction which is accounted for within Licensee on a
product-by-product basis), government mandated rebates and similar types of rebates (e.g., Pharmaceutical Price Regulation Scheme, Medicaid, clawback schemes and any other such scheme) 

  

	 	b)	Contract pricing chargebacks and changes to reserves of contract pricing chargebacks, such as periodic charges of wholesalers and chargebacks for price capping programs

  

	 	c)	Customer rebates and changes to reserves of customer rebates, such as volume (quantity) discounts or price discounts 

  

	 	d)	Returns and return reserves, such as in cases for spoiled, damaged, out-dated, rejected, returned Product sold, withdrawals and recalls, covering both resellable products and goods
which have to be destroyed 

  

	 	e)	Cash discounts 

  

	 	f)	Taxes, such as value added or sales taxes, government mandated exceptional taxes and other taxes directly linked to the gross sales amount 

 For the avoidance of doubt, the “Adjusted Gross Sales” on a Product-by-Product basis, means the same methodology as ROCHE consistently uses to
recognize sales in its financial reporting, which is in accordance with the then used International Financial Reporting Standards (IFRS), and is reviewed and approved by ROCHE’s external auditors. 
 1.33 Party 
 The term “Party” shall mean
EVOTEC or ROCHE, as the case may be, and “Parties” shall mean EVOTEC and ROCHE collectively. 
 1.34 Payment Term 
 The term “Payment Term” shall mean, with respect to each and every Product in a given country, the period of time commencing on the date of
First Commercial Sale of the first Product in such country and ending 10 (ten) years after the date of the First Commercial Sale of the first Product in such country. With regard to the calculation of the 10 (ten) year period, the EU shall be
considered as one country. 
 1.35 Patent Rights 
 The term “Patent Rights” shall mean all rights under any patent or patent application, in any country of the Territory, including any patents issuing on such patent application, and further including any substitution, extension or
supplementary protection certificate, reissue, reexamination, renewal, division, continuation or continuation-in-part of any of the foregoing. 
 1.36
Phase II Study 
 The term “Phase II Study” shall mean a human clinical trial, for which the primary endpoints include a
determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. § 312.21(b), and the foreign equivalent thereof. 
  

 11 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1.37 Phase III Study 
 The term “Phase III Study” shall mean a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to
obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c), and the foreign equivalent thereof. 
 1.38 [***] 
 The term “[***]” shall mean a
Compound, with the exception of EVT101 and EVT103, [***] containing receptors in vivo. 
 1.39 Product 
 The term “Product” shall mean any product, including without limitation any Combination Product containing a Compound as pharmaceutically active
agent, regardless of their finished forms or formulations or dosages. 
 1.40 Regulatory Authority 
 The term “Regulatory Authority” shall mean any national, supranational (e.g., the European Commission, the Council of the European Union, the
European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity including the FDA, in each country involved in the granting of Regulatory Approval for the Product.

 1.41 Regulatory Approval 
 The term
“Regulatory Approval” shall mean any approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations by Regulatory Authority, necessary for the manufacture and sale of a Product in the Field in a
regulatory jurisdiction in the Territory. 
 1.42 ROCHE Group 
 The term ROCHE Group shall mean collectively ROCHE and its Affiliates and Licensees. 
 1.43 ROCHE Know-How

 The term “ROCHE Know-How” shall mean all Know-How that ROCHE Controls. 
 1.44 ROCHE Patent Rights 
 The term “ROCHE Patent
Rights” shall mean all Patent Rights (i) Covering an Invention that ROCHE Controls and that relate to the discovery, manufacture, development or commercialization of a Product or (ii) Covering a Product. The term ROCHE Patent Rights
include ROCHE Base Patent Rights. 
 1.45 ROCHE Base Patent Rights 
 The term “ROCHE Base Patent Rights” shall mean any and all Patent Rights listed in Appendix 1 of this Agreement. 
  

 12 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 1.46 Licensee 
 The term “Licensee” means an entity to which ROCHE or its Affiliates have licensed rights relating to the Compound or Product. 
 1.47
Summary Report 
 The term “Summary Report” shall mean a high level bullet point summary covering the following development
activities: pre-clinical development; clinical development, regulatory filings, regulatory approvals. 
 1.48 Territory 
 The term “Territory” shall mean all countries of the world. 
 1.49 Third Party 
 The term “Third Party” shall mean a person or entity other than
(i) EVOTEC or any of its Affiliates or (ii) a member of the ROCHE Group. 
 1.50 Transaction 
 The term “Transaction” shall mean the sale and the purchase of the Assets contemplated by this Agreement and as described in Section 2.

 1.51 US 
 The term “US” shall
mean the United States of America and its territories and possessions. 
 1.52 VAT 
 The term “VAT” shall mean Value Added Tax. 
 2.
Sale and Purchase 
 a) EVOTEC hereby agrees to (i) return to ROCHE all rights and licenses granted to it by ROCHE under the License
Agreement, i.e., the license under the ROCHE Patent Rights and Roche Know-How, and under Roche’s interest in the Joint Patent Rights and Joint Know-How, and (ii) sell to ROCHE (1) all EVOTEC Patent Rights, (2) the EVOTEC Know-How
relating to Compounds within clause (i) of the definition of Compound in Section 1.10 and/or Products containing such a Compound, (3) EVOTEC’s interest in the Joint Patent Rights and (4) EVOTEC’s interest in
Joint-Know-How relating to Compounds within clause (i) of the definition of Compound in Section 1.10 and/or Products containing such a Compound, with economic effect as of the Closing Date. 
 ROCHE shall receive the originals of all documents relating to the Assets. However, EVOTEC shall be entitled to retain such originals to the extent that
EVOTEC is obliged by law to do so. In this case EVOTEC shall provide to ROCHE complete copies of the relevant documents and information. EVOTEC shall be entitled to keep copies of all documents provided to ROCHE. 
  

 13 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 b) Freedom to operate licenses to EVOTEC. ROCHE will grant to EVOTEC the necessary
freedom-to-operate licenses under any technologies used by EVOTEC. Such licenses, if any, will be granted in a written document signed by authorized signatories of the Parties. Such licenses will be cost-free, unless costs are due by ROCHE to third
parties. 
 c) License to EVOTEC for [***]. ROCHE grants to EVOTEC and its Affiliates an exclusive (even as to ROCHE) sub-licensable,
royalty-free, fully-paid, perpetual, non-terminable right and license to research, have researched, develop, have developed, register, have registered, use, have used, make, have made, import, have imported, export, have exported, market, have
marketed, distribute, have distributed, sell and have sold the [***] in any and all fields in the Territory 
 d) Use of [***]. Roche
shall have access to the [***], free of charge, for research and development purposes for any of ROCHE’s products, except as exclusively licensed to EVOTEC. Under this Section 2.d) the term [***] shall mean (i) the [***] in
development and (ii) the [***] registered and commercially available. 
 If ROCHE wishes to use the [***] for Roche’s marketed
products, then ROCHE shall have preferred access to use the [***]. 
 3. Signing Date, Closing Date and Closing 
 3.1 Signing Date 
 “Signing Date” shall be
the day when this Agreement has been signed on behalf of authorized representatives of all Parties. 
 3.2 Closing Date 
 “Closing Date” shall be the fifth Business Day after all Conditions Precedent have been met, unless otherwise agreed by the Parties. 

On the Closing Date, the Parties shall meet at 11:00 a.m. at the offices of EVOTEC, or at such other time and place as the Parties may mutually agree
upon, to confirm the satisfaction of the Conditions Precedent and to take, if any, all actions necessary to finalize the Transaction (herein “Closing”). 
 3.3 Closing 
 EVOTEC and ROCHE hereby agree that at Closing: 
  

	 	a)	EVOTEC’S interest and licenses to the ROCHE Patent Rights, Roche Know-How and ROCHE’s interest in the Joint Patent Rights and Joint Know-How shall be returned to ROCHE.

  

	 	b)	Title to the Assets shall pass to ROCHE. 

  

	 	c)	The transfer of possession of the physical assets sold and transferred to ROCHE according to Section 2 shall take place by grant of direct possession of the physical assets
sold passing to ROCHE on the Closing Date. This shall primarily be accomplished by ROCHE on the Closing Date taking possession of the Assets. 

  

	 	d)	To the extent that as of the Closing Date the physical assets are in the possession of Third Parties, EVOTEC hereby assigns effective as of the Closing Date its claims for surrender
with respect to such physical assets against these third parties to ROCHE. 

  

	 	e)	ROCHE shall pay the Purchase Price in accordance with Section 8. 

  

 14 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 4. Conditions to Closing, Covenants between Signing and Closing 
 4.1 Conditions to the Parties’ Obligations 
 The
obligation of the Parties to consummate the Transaction pursuant to this Agreement is subject to the satisfaction of the following conditions (the “Conditions Precedent”): 
  

	 	a)	ROCHE has exercised its Option Right under the License Agreement by giving written notice to EVOTEC. 

  

	 	b)	All filings have been made and all waiting periods have expired or been terminated in relation to the Transaction under the Hart-Scott-Rodino Anti-Trust Improvements Act of 1976, as
amended, and any foreign equivalent thereof, if any. 

  

	 	c)	The obligation of ROCHE to consummate the Transaction pursuant to this Agreement is subject to the satisfaction of the following additional Conditions Precedent which may, all or in
part, be waived by ROCHE in its sole discretion: 

  

	 	(i)	All of the guaranties of EVOTEC set forth in Section 13 are true and correct as of the Closing Date. 

  

	 	(ii)	No Material Adverse Change to the Assets has occurred. 

  

	 	(iii)	EVOTEC is not in violation of Section 4.3. 

 4.2 No Refusal or
Delay 
 No Party shall be entitled to refuse or delay the consummation of any of the Transaction for any reason other than the
non-satisfaction of any Conditions Precedent as set forth in Section 4.1. 
 4.3 Conduct of Business and Other 
 From the Signing Date to the Closing Date EVOTEC shall be obligated to the following: 
  

	 	a)	the business activities of EVOTEC regarding the Assets shall be conducted in the ordinary course of business; 

  

	 	b)	comply with all terms set forth in this Agreement; 

  

	 	c)	maintain all Patent Rights related to the Assets in accordance with the License Agreement; 

  

	 	d)	disclose to ROCHE all events and circumstances which ROCHE in its reasonable judgment may deem relevant for the accomplishment of this Agreement; 

  

	 	e)	refrain from granting any rights, including, without limitation, the sale and transfer, regarding the Assets to Third Parties; 

  

	 	f)	upon ROCHE’s reasonable request, give ROCHE access to all information relating to the Assets. 

 5. EVOTEC’s Post Closing Obligations 
 5.1 Cooperation 
 After the Closing, the Parties shall cooperate and assist each other in good faith as is reasonably necessary and appropriate to ensure a further smooth
transfer of the Assets to ROCHE. Upon ROCHE’s reasonable request, and to the extent not already transferred, EVOTEC shall promptly give ROCHE complete access to all data, 
  

 15 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 
material and information relating to the Assets. In particular, to the extent that following Closing Assets are yet to be transferred to ROCHE, EVOTEC is
obliged to maintain all documents, material and data related to the Assets in the ordinary course of business. 
 5.2 Disclosure of Know-How and
Information 
 Promptly after its availability, EVOTEC shall disclose to ROCHE without undue delay all further Know-How and information
related to the Assets, including but not limited to any Know-How and information generated under Section 5.4, that come to EVOTEC’s attention after the Closing. Upon ROCHE’s request EVOTEC shall deliver to ROCHE all of such Know-How
and information. 
 5.3 Transfer of Regulatory Documents 
 Promptly after the Closing Date or promptly after its availability pursuant to Section 5.4, EVOTEC shall transfer and assign to ROCHE all INDs in its possession and control and shall provide to ROCHE copies of
all correspondence relating to Products with the Regulatory Authorities. In addition, at a date defined by ROCHE, EVOTEC shall transfer and assign to ROCHE any regulatory dossiers containing information necessary or useful to ROCHE in connection
with its regulatory filings for all Products, including, but not limited to clinical trial dossiers, regulatory correspondence, Regulatory Authority meeting minutes and study reports from completed non-clinical and clinical studies. For all
completed study reports, EVOTEC shall provide necessary documentation to confirm data reliability, including but not limited to original author signatures, raw data lists, GLP and GCP compliance information. All documentation is to be provided in
English. 
 Promptly after the Closing Date, EVOTEC shall transfer to ROCHE the historical clinical safety data prior to ROCHE starting
clinical trial enrollment activities. It is agreed that after transfer of historical clinical safety data (Safety information on serious adverse events shall be provided in CIOMS format and Safety information on non-serious adverse events shall be
provided in English Line Listing format). ROCHE shall be solely responsible for maintaining the global safety database for the Product. 
 5.4 Ongoing
Studies 
 a) Ongoing Studies under the Development Plan 
 Notwithstanding Section 5.3, if, at Closing Date, EVOTEC conducts any non-clinical or clinical studies under the agreed Development Plan (as defined in the License Agreement), then (i) EVOTEC shall use
Commercially Reasonable Efforts (as defined for EVOTEC in the License Agreement) to complete such studies, (ii) EVOTEC shall use Commercially Reasonable Efforts (as defined for EVOTEC in the License Agreement) to finalize all study reports in a
format ready for submission to Regulatory Authorities, e.g. including all appendices and listings and quality controlled and (iii) ROCHE shall assume the cost for such studies under an agreement to be negotiated between the Parties in good
faith. 
 b) Ongoing Studies outside the Development Plan 
 Notwithstanding Section 5.3, if, at Closing Date, EVOTEC conducts and non-clinical or clinical studies outside the agreed Development Plan (as defined in the License Agreement), then ROCHE has the right but not
the obligation to (I) request the transfer of such studies to ROCHE or to (II) ask EVOTEC to continue the studies at ROCHE’s future costs or (III) to decline interest in (I) and (II). 
 (I) If ROCHE requests the transfer of such studies to ROCHE, then the Parties will discuss in good faith the modalities of such transfer and execute a
Pharmacovigilance Agreement, if necessary. 
  

 16 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 (II) If ROCHE asks EVOTEC to continue the studies, then (i) EVOTEC shall use Commercially Reasonable
Efforts (as defined for EVOTEC in the License Agreement) to complete such studies, (ii) EVOTEC shall use Commercially Reasonable Efforts (as defined for EVOTEC in the License Agreement) to finalize all study reports in a format ready for
submission to Regulatory Authorities, e.g. including all appendices and listings and quality controlled and (iii) ROCHE shall assume the future cost for such studies under an agreement to be negotiated between the Parties in good faith.

 (III) If ROCHE declines (I) and (II) within thirty (30) days after Closing, then, except for any activities conducted under the
Development Plan, EVOTEC shall have the right but not the obligation to continue, at EVOTEC’s costs, non-clinical development activities and clinical, including preparatory activities, ongoing as of the Closing Date. 
 Notwithstanding the foregoing, EVOTEC shall not initiate any new activities relating to Compounds and Products after the Closing Date. 
 5.5 Pharmacoviligance 
 ROCHE and EVOTEC agree that
they will execute a separate Pharmacovigilance Agreement, if legally required, specifying the procedures and timeframes for compliance with the applicable laws and regulations pertaining to safety reporting and its related activities of the
Compounds and Products, 
 5.6 Point of Contact 
 Upon ROCHE’s request, EVOTEC shall provide ROCHE with a point of contact at EVOTEC who will work with ROCHE for a period of six (6) months after the Closing Date to address any questions relating to the Assets. 
 6. Manufacture and Supply 
 As from the Closing Date,
ROCHE shall assume full responsibility for the manufacture of Compounds and Product, for both clinical and commercial supply, either by itself or through Third Parties. Promptly following the Closing Date, the parties shall collaborate for the
transfer of all data, material and information relating to the Assets to ensure a seamless transition of manufacturing and technical development activities. 
 7. Regulatory 
 After the Closing and subject to Section 5.3 and 5.4, ROCHE, at its sole cost, shall pursue all
regulatory affairs related to the Compounds and the Products in the Territory including the preparation and filing of applications for regulatory approval, as well as any or all governmental approvals required to develop, have developed, make, have
made, use, have used, manufacture, have manufactured, import, have imported, sell and have sold Compounds and Products. ROCHE shall be responsible for pursuing, compiling and submitting all regulatory filing documentation, and for interacting with
regulatory agencies, for all Products in all countries in the Territory. ROCHE or its Affiliates shall own and file in their discretion all regulatory filings and regulatory approvals for all Products in all countries of the Territory. 

ROCHE, at its sole cost, shall report to appropriate authorities in accordance with local requirements all adverse events related to use of the
Products in the Territory. 
  

 17 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 8. Purchase Price 
 The Purchase Price for the Assets shall amount to sixty-five million US dollars (US$ 65 million) plus applicable VAT and sales taxes in the amount statutorily required, if any, and shall hereinafter be referred to as
the “Purchase Price”. 
 The Purchase Price shall become due and payable at Closing upon contemporaneous transfer and assignment of
the Assets as set forth in Section 3.3. The Purchase Price shall be non-refundable in the event of the transfer of assets to EVOTEC as stipulated in Section 17 of this Agreement. 
 9. Further Payments 
 9.1 Development Event Payments

 ROCHE obligates itself to make further payments to EVOTEC subject to the achievement of certain steps in the process to develop the
Compounds and Products. 
 ROCHE shall pay up to EVOTEC a total of US$ one hundred twenty million (US$ 120 million) in relation to the
development of the Compounds and Products in the Territory. For any indication, ROCHE shall pay to EVOTEC according to the following schedule of events, as applicable: 
  

				
	 Event
	  	Payment
	 Phase II Study Initiation
	  	US$	 [***]
	 Phase III Study Initiation
	  	US$	 [***]
	 NDA Filing of first indication outside of Japan
	  	US$	 [***]
	 NDA Filing of first indication in Japan
	  	US$	 [***]
	 First Commercial Sale outside of Japan
	  	US$	 [***]
	 First Commercial Sale in Japan
	  	US$	 [***]
	 Total
	  	US$	 120.00 million

 Each development event payment shall only be paid no more than once, the first time the first
Product reaches such events in any indication, regardless of the number of times such events are subsequently reached for a given Product in the same or any other indication or for a given indication for the same or any other Product. 
 Upon reaching development events, ROCHE shall timely notify EVOTEC and development event payments shall be paid by ROCHE to EVOTEC within forty five
(45) days from occurrence of the applicable event and receipt of an invoice from EVOTEC. 
 9.2 Sales Based Events 
 ROCHE obligates itself to make further payments to EVOTEC subject to the achievement of the launch of a Product. 
 ROCHE shall pay to EVOTEC up to a total of US$ [***] (US$ [***]) based on aggregate Calendar Year Net Sales in the Territory of the first Product sold:

  

			
	 Net Sales Threshold
	  	Payment
	 First time total Calendar Year Net Sales in the Territory of the first Product exceed US$ [***]
	  	US$ [***]
	 First time total Calendar Year Net Sales in the Territory of the first Product exceed US$ [***]
	  	US$ [***]
	 First time total Calendar Year Net Sales in the Territory of the first Product exceed US$ [***]
	  	US$ [***]
	 TOTAL
	  	US$ [***]

  

 18 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 Each of the sales based event payments shall be paid no more than once under this Agreement, at first
occurrence of the event in a Calendar Year for the first Product launched in the Territory and shall be non refundable and non creditable. 
 9.3
Commercial Payments 
 ROCHE obligates itself to make further payments to EVOTEC subject to the achievement of the launch of Products.

 a) Payment Term 
 Payments shall be made by
ROCHE on Net Sales of any Product on a country-by-country and Product-by-Product basis during the Payment Term. 
 The following payment
rates shall apply to the respective tiers of aggregate Calendar Year Net Sales of a Product per geographic area of the Territory, on an incremental basis, as follows: 
  

	 	i)	For aggregate countries other than Japan 

  

				
	 Tier of Calendar Year
 Net Sales in million US$
	  	Percent (%) of Net Sales	 
	 < [***]
	  	[	***]% 
		
	 > [***]—[***]
	  	[	***]% 
		
	 > [***]—[***]
	  	[	***]% 
		
	 > [***]
	  	[	***]% 

  

	 	ii)	For Japan: 

  

				
	 Tier of Calendar Year
 Net Sales in million US$
	  	Percent (%) of Net Sales	 
	 < [***]
	  	[	***]% 
		
	 > [***]—[***]
	  	[	***]% 
		
	 > [***]—[***]
	  	[	***]% 
		
	 > [***]
	  	[	***]% 

 For example, if Net Sales of a Product in the countries other than Japan for a given Calendar Year
are US$ 1’600 million, then the royalty rate applicable to such Net Sales of such Product for that Calendar Year shall be calculated as follows: US$ [***] x [***]% = US$[***]; US$ [***] x [***]% = US$[***]; US$ [***] x [***]% = US$ $[***];
with total royalties due = US$[***]. 
 For the purpose of calculating royalties of a Product, Calendar Year Net Sales shall be subject to
the following adjustments: 
 b) Combination Product 
 If ROCHE or its Affiliates intend to sell a Combination Product, then the Parties shall meet approximately one (1) year prior to the anticipated First Commercial Sale of such Combination Product to negotiate in good 
  

 19 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 
faith and agree to an appropriate adjustment to Net Sales to reflect the relative pharmaceutical activity of the Product and the other pharmaceutically
active agent(s) contained in the Combination Product. If, after such good faith negotiations not to exceed ninety (90) days, the Parties cannot agree to an appropriate adjustment, the dispute shall be initially referred to the executive
officers of the Parties in accordance with Section 18.1.2. Should the Parties fail to agree within sixty (60) days of such referral, then the Net Sales shall equal such portion of the Net Sales of the Combination Product which is
equivalent to the relative contribution to the pharmaceutical activity of the Product within the Combination Product, as determined by an Expert jointly appointed by the Parties within a further thirty (30) days. In the absence of an agreement
on the appointment of the Expert, either Party may have such Expert appointed by the ordinary courts having jurisdiction. The decision of the Expert shall be final and binding on the Parties and the fees of the Expert shall be shared equally between
the Parties. 
 c) Third Party Payments 
 ROCHE
shall pay and be responsible for the entire consideration owed to any Third Party in relation to Third Party intellectual property rights that would be infringed by the manufacture, sale, use, importation or otherwise disposal of Product by ROCHE.
If ROCHE is obligated to remit payments to a Third Party in relation to third party intellectual property that would be infringed by the making or the marketing of a Product, ROCHE shall be permitted to offset up to twenty five percent (25%) of
any payments due to such Third Party against any royalties otherwise owed by ROCHE to EVOTEC, provided that in no event shall the effective average payment rate due to EVOTEC be reduced to below seventy five percent (75%) of the average payment
rate which would have been otherwise due to EVOTEC absent such adjustment related to Third Party payments. 
 9.4 Final Payment 
 ROCHE may, at any time after the First Commercial Sale of a Product in its free discretion make a final payment to EVOTEC with respect to all commercial
payments thereafter payable pursuant to Sections 9.2 and 9.3 with respect to such Product (hereinafter also referred to as: “Final Payment”). 
 ROCHE may choose to make a Final Payment to EVOTEC for a given Product in a given geographical area (USA, Japan, EU and all other countries) or for all Products for which a First Commercial Sale has occurred in the
Territory, by providing EVOTEC with written notice of such choice and paying to EVOTEC, in lieu of the all commercial payments thereafter payable pursuant to Sections 9.2 and 9.3 with respect to such Product, a single or an agreed upon set of fixed
payments which will be negotiated in good faith between EVOTEC and ROCHE. In such case, the Payment Term for such Product in such geographic area shall be deemed ended. 
 10. Accounting and reporting 
 10.1 Timing of Payments 
 ROCHE shall calculate royalties on Net Sales quarterly as of March 31, June 30, September 30 and December 31 (each being the
last day of an “Accounting Period”) and shall pay royalties on Net Sales within the ninety (90) days after the end of each Accounting Period in which such Net Sales occur. 
 10.2 Late Payment 
 Any payment under this Agreement that is not paid on or before the date such
payment is due shall bear interest, to the extent permitted by applicable law, at two (2) percentage points above the average one-month Euro Interbank Offered Rate (EURIBOR), as reported by Reuters from time to time, calculated on the number of
days such payment is overdue. 
  

 20 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 10.3 Method of Payment 
 All royalties on Net Sales in all countries shall be paid by ROCHE in US Dollars. 
 10.4 Currency Conversion

 When calculating the Adjusted Gross Sales for any country, ROCHE shall convert the amount of such sales in currencies other than US
Dollars into US Dollars using for internal foreign currency translation ROCHE’s then current standard practices actually used on a consistent basis. 
 10.5 Reporting 
 With each payment due under Section 9.3, ROCHE shall provide EVOTEC in writing for the relevant
Calendar Quarter on a Product-by-Product basis the following information: 
  

	 	a)	Adjusted Gross Sales in each country in local currency; 

  

	 	b)	Adjusted Gross Sales converted in US Dollars; 

  

	 	c)	Net Sales in each country in US Dollars; 

  

	 	d)	Adjustments made pursuant to Section 9.3; 

  

	 	e)	Net Sales after adjustments made pursuant to Section 9.3; 

  

	 	f)	Total Net Sales in the Territory in US Dollars; 

  

	 	g)	Total amount payable to EVOTEC in US Dollars; and 

  

	 	h)	Exchange rates used for the conversions made under Section 10.4 above. 

 The report for the fourth Calendar Quarter shall include a list of all countries in which a Product is sold in the Territory for the applicable Calendar Year. 
 11. Taxes 
 EVOTEC shall pay all sales, turnover,
income, revenue, value added, and other taxes levied on account of any payments accruing or made to EVOTEC under this Agreement. 
 If
provision is made in law or regulation of any country for withholding of taxes of any type, levies or other charges with respect to any amounts payable under this Agreement to EVOTEC, then ROCHE shall promptly pay such tax, levy or charge for and on
behalf of EVOTEC to the proper governmental authority, and shall promptly furnish EVOTEC with receipt of payment. ROCHE shall be entitled to deduct any such tax, levy or charge actually paid from payments due to EVOTEC or be promptly reimbursed by
EVOTEC if no further payments are due to EVOTEC. Each Party agrees to reasonably assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in
minimizing the amount required to be so withheld or deducted. 
 12. Auditing 
 12.1 Auditing 
 ROCHE shall keep, and shall require its and its Affiliates and Licensees to keep,
full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties 
  

 21 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 
payable under this Agreement. Such books of accounts shall be kept at their principal place of business. At the expense of EVOTEC, EVOTEC has the right to
engage ROCHE’s officially appointed worldwide independent public accountant to perform, on behalf of EVOTEC an audit of such books and records of ROCHE and its Affiliates, that are deemed necessary by ROCHE’s independent public accountant
to report on Net Sales of Product for the period or periods requested by EVOTEC and the correctness of any report or payments made under this Agreement. 
 Upon timely request and at least sixty (60) working days’ prior written notice from EVOTEC, such audit shall be conducted in the countries specifically requested by EVOTEC, during regular business hours in
such a manner as to not unnecessarily interfere with ROCHE’s normal business activities, and shall be limited to results in the two (2) calendar years prior to audit notification. 
 Such audit shall not be performed more frequently than once per Calendar Year nor more frequently than once with respect to records covering any specific
period of time. 
 All information, data documents and abstracts herein referred to shall be used only for the purpose of verifying payment
statements, shall be treated as ROCHE Confidential Information subject to the obligations of this Agreement and need neither be retained more than one (1) year after completion of an audit hereof, if an audit has been requested; nor more than
two (2) years from the end of the calendar year to which each shall pertain; nor more than one (1) year after the date of termination of this Agreement. 
 12.2 Sharing of draft reports 
 The auditors shall share all draft reports with ROCHE before the draft report is shared with
EVOTEC and before the final document is issued; the auditors shall not interpret the agreement. The final report shall be shared by ROCHE and EVOTEC. 
 12.3 Over-or Underpayment 
 If the audit reveals an overpayment, EVOTEC shall reimburse ROCHE for the amount of the
overpayment within thirty (30) days. If the audit reveals an underpayment, ROCHE shall make up such underpayment with the next payment. ROCHE shall pay for the audit costs if the underpayment of ROCHE exceeds 5% of the amount due to EVOTEC for
the total period being audited. Section 10.2 shall apply to this Section 12.3. 
 12.4 Duration of Audit Rights 
 The failure of EVOTEC to request verification of any payment calculation within the period during which corresponding records must be maintained under
this Section 12 will be deemed to be acceptance of the payments and reports. 
 13. Guarantees of EVOTEC 
 EVOTEC grants to ROCHE independent guarantees for the facts and circumstances set out in this Section 13 and within the scope defined in, and subject
to the limitations pursuant to Section 14. 
 All guarantees following hereinafter shall be given as of the Signing Date and EVOTEC
shall cause such guarantees to be true and correct until and as of the Closing Date. 
  

 22 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 13.1 Incorporation of EVOTEC 
 EVOTEC is a corporation duly incorporated, validly existing and in good standing under the laws of Germany and has all requisite power and authority, corporate or otherwise, to own its assets and to carry out its
business and to execute, deliver and perform this Agreement, and the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action and the Transaction does not and will not 
  

	 	(a)	require any further consent or approval of any corporate body of EVOTEC, 

  

	 	(b)	violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or

  

	 	(c)	conflict with, or result in a breach of, the articles of association or by-laws of EVOTEC. 

 13.2 Assets 
 To the best knowledge of EVOTEC, EVOTEC is entitled to freely dispose of the Assets as
set forth in Section 2 without requiring the further consent of any Third Party and without such disposal infringing any rights of a Third Party. In particular, EVOTEC is not under any obligation to any person, or entity, contractual or
otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations hereunder and has all power and authority under all instruments or agreements
to which it is a party to enter into this Agreement and to perform its obligations hereunder. EVOTEC holds legal and economic title to the EVOTEC Patent Rights and EVOTEC’s interest in the Joint Patent Rights. The Assets are free from any
encumbrances or other rights granted by EVOTEC to any Third Party. 
 13.3 Know-How and Intellectual Property Rights 
 To the best knowledge of EVOTEC, 
  

	 	(i)	the activities of EVOTEC prior to the Closing Date in relation to the use of EVT 101 and EVT 103 have not been in the past and are not infringing any intellectual property rights of
Third Parties, and 

  

	 	(ii)	no litigation is pending or threatened in writing wherein EVOTEC is accused of infringing or otherwise violating any Intellectual Property Rights or Patent Rights of third parties
in relation to the Assets, nor has EVOTEC received written notice of any such infringement or violation, which have not been disclosed in writing to ROCHE. 

 EVOTEC has not transferred for economic benefit to any Third Party any Know-How sold to ROCHE pursuant to this Agreement. 
 EVOTEC makes no representation concerning the ability of ROCHE to utilize the Assets or to develop or commercialize any Compound or Product, including without limitation the ability of ROCHE to repeat results
previously achieved by EVOTEC. 
 To the best knowledge of EVOTEC, all EVOTEC Patent Rights are validly existing, no other party holds title
or whatsoever rights to such EVOTEC Patent Rights and no nullity procedure has been filed with respect to the EVOTEC Patent Rights. 
  

 23 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 13.4 Litigation 
 EVOTEC is not involved in any kind of proceedings pending before courts or administrative agencies or arbitration tribunals relating to the Assets and EVOTEC has not received any written threat of any such
proceedings, which have not been disclosed in writing to ROCHE. 
 13.5 All of NMDA program 
 All assets and information relating to the Assets provided by EVOTEC to ROCHE pursuant to this Agreement and the information previously given to ROCHE
represent all of the material information relating to the Assets known to EVOTEC. To the best knowledge of EVOTEC, EVOTEC has not withheld any material data and/or information relating to the Assets. 
 13.6 Taxes 
 To the best knowledge of EVOTEC, no taxes
relating to the Assets are due or could become due relating to the activities of EVOTEC prior to the Signing Date or the activities of EVOTEC following the transfer of the Assets from EVOTEC to ROCHE which have not been disclosed in writing to
ROCHE. 
 13.7 Full disclosure 
 No
information provided to ROCHE is knowingly misleading and no material information regarding the Assets was knowingly withheld. To the best knowledge of EVOTEC, no information relating to the Assets has been knowingly withheld that could reasonably
have had an influence on ROCHE’s decision to execute this Agreement. To the best knowledge of EVOTEC, no circumstances exist that might be expected in the future to have a material adverse effect upon the Assets as a whole. 
 13.8 Safety Data 
 EVOTEC has disclosed to ROCHE
(i) all material results of all preclinical testing and human clinical testing of the Compounds in its possession or control and (ii) all material information in its possession or control concerning side effects, injury, toxicity or
sensitivity reaction and incidents or severity thereof with respect to the Compounds. 
 13.9 Inventors 
 EVOTEC has obtained the assignment of all interest and all rights thereunder with respect to the EVOTEC Patent Rights necessary to execute the transfer
and assignment made hereunder. All of EVOTEC’s employees, officers and consultants have executed agreements requiring assignment to EVOTEC of all inventions relating to Compounds or Products made by such individuals during the course of and as
a result of their association with EVOTEC. 
 13.10 No Claims 
 There are no claims or investigations (other than with respect to the Parties’ HSR Filings, or other foreign filings, if any), pending or threatened in writing against EVOTEC or any of its Affiliates, at Law or
in equity, or before or by any governmental authority relating to the matters contemplated under this Agreement or that would materially adversely affect EVOTEC’s ability to perform its obligations hereunder. 
  

 24 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 13.11 No Conflict 
 Neither EVOTEC nor any of its Affiliates is or will be under any obligation to any person, contractual or otherwise, that is conflicting with the terms of this Agreement or that would impede the fulfillment of
EVOTEC’s obligations hereunder. 
 14. EVOTEC’s Liability And Limitations to EVOTEC’s Liabilities; indemnification with respect to
employees of EVOTEC 
 14.1 Scope of Guarantees 
 a)
General 
 In the event of any breach or non-fulfillment by EVOTEC of any of the guarantees set forth in Section 13, EVOTEC shall be
liable within the limits of this Section 14 for putting ROCHE into the same position that it would have been in if the guarantee had been correct or not been breached, or, if and to the extent EVOTEC fails to cure the breach or non-fulfillment
within a period of three months after notification by ROCHE, to pay damages, provided, however, that the guarantees set forth in Section 13 shall not cover internal administration or overhead costs of ROCHE, loss of profit, loss of goodwill or
reputational damage, punitive damages, or any argument that the Purchase Price was calculated upon incorrect assumptions. 
 b) De Minimis Amount 

EVOTEC’s liability pursuant to this Section 14 for breach of the guarantees set forth in Section 13 shall only cover those cases in
which ROCHE, due to a breach of a guarantee, suffers recoverable loss exceeding US Dollar four hundred thousand (US $ 400,000.00) (the “De Minimis Amount”). For the avoidance of doubt, in the event that ROCHE experiences losses exceeding
the De Minimis Amount, ROCHE shall be entitled to claim the full amount of its losses. 
 c) Mitigation 
 EVOTEC shall not be liable for, and ROCHE shall not be entitled to bring, any claim under or in connection with this Agreement if and to the extent that
such claims result from ROCHE causing the relevant facts or circumstances underlying the breach of the guarantee or a failure by ROCHE to avoid or to mitigate damages. 
 d) Exclusion of Liability 
 EVOTEC shall not be liable for, and ROCHE shall not be entitled to bring, any
claim under or in connection with this Agreement if and to the extent ROCHE has, at the time such claim is asserted vis-à-vis EVOTEC, received full indemnification from a Third Party. In the event that ROCHE is in a position to bring such
claims to EVOTEC and also to a Third Party, ROCHE shall first exhaust its claims against all Third Parties prior to bringing any claim against EVOTEC. In addition, EVOTEC shall not be liable for, and ROCHE shall not be entitled to bring, any claim
for a breach or non-fulfillment of a guarantee under or in connection with this Agreement if (i) EVOTEC can demonstrate that ROCHE had knowledge of the facts or circumstances constituting the breach or non-fulfillment by EVOTEC of the relevant
guarantee at or prior to the time of the Signing or (ii) EVOTEC can demonstrate that ROCHE had knowledge of the facts or circumstances constituting the breach or non-fulfillment by EVOTEC of the relevant guarantee at or prior to the time of the
Closing, provided these facts or circumstances became known to EVOTEC only after Signing and were brought to ROCHE’s attention in writing without undue delay. 
  

 25 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 e) Knowledgeable Persons on EVOTEC’s Side 
 If guarantees set forth in Section 13 refer to the best knowledge of EVOTEC, this means the knowledge of all senior employees (i.e. authorized
officer “Prokurist” and higher) of EVOTEC who have been involved in the development of the Compounds and Products and/or the preparation of the transfer of the Assets at any time in the period between the July 31, 2008 and the Closing
Date. 
 f) Overall Scope of EVOTEC’s Liability pursuant to this Agreement 
 EVOTEC’s aggregate liability pursuant to this Agreement other than its liability pursuant to Section 14.2 shall be limited to US Dollars [***] ($[***]). In the event of willful misconduct, fraudulent
concealment or willful deceit, however, EVOTEC’s liability shall not be limited. 
 g) Limitation 
 All claims of ROCHE arising in connection with this Agreement other than those arising from EVOTEC’s obligations as stipulated in Section 14.2
(Employees of EVOTEC) shall be time-barred twelve (12) full calendar months from Closing. 
 h) Sole Remedy 
 ROCHE agrees that its remedies with respect to any and all damage or loss incurred by it relating to the subject matter of this Agreement shall
exclusively be governed by the provisions of this Agreement. To the extent legally permissible, all other statutory or contractual claims or remedies relating to the subject matter of this Agreement other than those on the grounds as stated in
Section 14.1 f) second sentence (Overall scope of liability), are expressly excluded, in particular, any claims for reduction of the purchase price or improvement based on faultiness of the object of purchase, recession, challenge, damage
claims for breaching an obligation in connection with the preparation or negotiation of this Agreement by the parties or their representatives prior to the conclusion of this Agreement (culpa in contrahendo). The provisions of Section 17
(Transfer of Rights) remain unaffected. 
 14.2 Indemnification with respect to employees of EVOTEC 
  

	a)	The Parties jointly assume that the return of Roche’s rights and the sale and transfer of the Assets does not constitute a transfer of undertaking within the meaning of sec.
613a of the German Civil Code (BGB). Accordingly, the Parties further assume that no employees of EVOTEC will transfer across to ROCHE under sec. 613a German Civil Code and that ROCHE will not be obliged to reinstate any former employees of EVOTEC
because of the Transaction. 

  

	b)	If an employee of EVOTEC should claim that his employment with EVOTEC has transferred across to ROCHE under sec. 613a German Civil Code because of the Transaction, then ROCHE shall

  

	 	(i)	immediately inform EVOTEC in writing and 

  

	 	(ii)	take all necessary steps to terminate, on a precautionary basis, any possibly existing employment relationship between ROCHE and such employee, including, but not limited to, the
issuance of a notice letter and the offering of a termination agreement. 

 This applies mutatis mutandis where a former
employee of EVOTEC should claim to be reinstated by ROCHE in connection with sec. 613a German Civil Code because of the Transaction. 
  

 26 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

	c)	If, contrary to the Parties’ common understanding, a competent court of last instance, or, where EVOTEC agrees with ROCHE in writing not to appeal the decision of a competent
inferior court, such inferior court should hold that any employee of EVOTEC has transferred across to ROCHE under sec. 613a German Civil Code because of the Transaction or that, because of the Transaction, then ROCHE is obliged to reinstate any
former employee of EVOTEC (hereinafter “Transferring Employee”), EVOTEC shall indemnify ROCHE for 

  

	 	(i)	all claims of whatever nature and amount in connection with the employees possibly transferred, including but not limited to base salary, any social security contributions and any
fringe benefits (e.g. holiday pay, bonus) the Transferring Employee is entitled to during the period between the Transferring Employee’s transfer to ROCHE and the first possible date of termination of the Transferring Employee’s employment
but at least until the date when the termination of such a transferred employment is declared legally valid; 

  

	 	(ii)	the cost of a severance payment to the Transferring Employee in consideration for the Transferring Employee accepting the termination of his employment provided that the amount to
be paid to the Transferring Employee has been agreed between EVOTEC and ROCHE in writing before the payment is made; 

  

	 	(iii)	all reasonable legal advisory fees incurred by ROCHE 

  

	 	(x)	in litigation with the Transferring Employee on a transfer of such employee’s employment to ROCHE or an obligation of ROCHE to reinstate such employee or

  

	 	(y)	in connection with the termination of such employee. 

  

	 	    	The parties agree that EVOTEC shall be entitled to choose the legal advisor to render the aforementioned legal services to ROCHE. 

  

	d)	EVOTEC shall not be obliged to indemnify ROCHE under Section 14.2 c) if ROCHE effectively employs the Transferring Employee by its own decision prior to or within one year
following the Closing Date. 

  

	e)	The indemnification payment described in Section 14.2. c) shall be payable within one month following the decision of the competent court of last instance or, where EVOTEC
agrees with ROCHE in writing not to appeal the decision of a competent inferior court, within one month following the serving of the full judgment of the such court to both Parties upon receipt by EVOTEC of a proper invoice evidencing the payments
ROCHE has made to the Transferring Employee. 

 15. Guarantee of ROCHE 
 15.1 Representation 
 ROCHE hereby guarantees by way of an independent guarantee (selbständiges
Garantieversprechen) that 
  

	 	a)	it is a corporation duly incorporated, validly existing and in good standing under the laws of Switzerland and has all requisite power and authority, corporate or otherwise, to
carry out its business, to own its assets and to execute, deliver and perform this Agreement; 

  

	 	b)	the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action and the Transaction do not and will not

  

	 	(i)	require any further consent or approval of any corporate body, 

  

	 	(ii)	violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or

  

 27 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

	 	(iii)	conflict with, or result in a breach of, the articles of association or by-laws of ROCHE; and 

  

	 	c)	is not under any obligation to any person, or entity, contractual or otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would
impede the diligent and complete fulfillment of its obligations hereunder and that it has all power and authority under all instruments or agreements to which it is a party to enter into this Agreement and to perform its obligations hereunder.

 15.2 Indemnification 
 If
ROCHE is in breach of the guarantee pursuant to this Section 15, ROCHE shall indemnify and hold harmless EVOTEC from any loss incurred by EVOTEC. All claims of EVOTEC arising under this Section 15 shall be time-barred after twelve full
calendar months from Closing. 
 15.3 Further Indemnification 
 ROCHE shall further indemnify and hold harmless EVOTEC from all liabilities, losses and damages in connection with the Assets that occur after the Closing Date for so long as a Product is being developed or
commercialized by ROCHE and thereafter with respect to any Product that has been manufactured or sold by the ROCHE Group or a Licensee of ROCHE. The obligation of ROCHE pursuant to this Section 15.3 shall cease in the event of a transfer to
EVOTEC as stipulated in Section 17 (Transfer of Rights). 
 16. Covenants of ROCHE 
 16.1 Development and Commercialisation of a Product by ROCHE 
 ROCHE shall use Commercially Reasonable
Efforts with regard to the development and commercialization of the Compounds and Products. 
 16.2 EVOTEC’s Rights to Information 
 In order to enable EVOTEC to monitor the progress of the development and commercialization of a Product; 
  

	 	(a)	From the Closing Date until the expiration of the Payment Term, ROCHE shall keep EVOTEC fully informed of the progress of its Commercially Reasonable Efforts to develop and
commercialise a Product through written Summary Report, such Summary Report to be sent to EVOTEC at the end of each Calendar Year 

 Any such information shall be sent to EVOTEC and shall be considered Confidential Information. 
  

	 	(b)	From the Closing Date until the expiration of the Payment Term, EVOTEC shall be entitled to request either a telephone conference call or a meeting within every full Calendar Year
to verify if ROCHE uses Commercially Reasonable Efforts. The appointed Alliance Director of ROCHE shall facilitate any such telephone conference call or meeting with appropriate ROCHE employees 

 16.3 Payment 
 Roche shall make the payments as set
forth under Section 8 and Section 9. 
  

 28 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 16.4 Publications 
 If EVOTEC wishes to publish the results of its development efforts with respect to the Assets which were achieved until the Closing of this Agreement, EVOTEC shall submit to ROCHE a draft of the proposed manuscript
for review, comment and consideration at least four (4) weeks prior to any submission for publication or other public disclosure. EVOTEC further agrees, upon written request of ROCHE, not to submit such manuscript for publication for an
additional sixty (60) days in order to allow for actions to be taken, which are necessary to preserve rights to patents or to refrain from publication. ROCHE shall have the right to object to such publications of EVOTEC. 
 16.5 Failure of ROCHE to comply with Covenants under Sections 16.1, 16.2 or 16.3 
 In the event that EVOTEC asserts that ROCHE has failed to comply with its covenants as stipulated in Sections 16.1, 16.2 or 16.3 above, EVOTEC shall so notify ROCHE in writing and state the grounds for its assertion.
Within sixty (60) days of its receipt of such notice, ROCHE shall respond in writing and, if it asserts that it has not failed to comply with its covenants as stipulated in Sections 16.1, 16.2 or 16.3 above, provide EVOTEC with sufficient
information to that effect. Unless EVOTEC agrees that ROCHE has not failed to comply with its covenants as stipulated in Sections 16.1, 16.2 or 16.3 above, the matter shall be resolved in accordance with Sections 18.3 and 18.4. In the event that a
party takes legal action and the arbitration tribunal holds that ROCHE has failed to comply with its covenants as stipulated in Sections 16.1, 16.2 or 16.3 above, Roche shall have the right to exercise its right to license and transfer the Assets as
set forth in Section 17 within ninety (90) days following delivery of the respective final decision of the court of arbitration to ROCHE. In the event that ROCHE fails to do so, EVOTEC shall be entitled to exercise the right in
Section 17 on behalf of ROCHE by written notice to ROCHE, and upon delivery of such notice, the license and transfer in Section 17 will take effect immediately. EVOTEC shall be obligated to exercise its right within sixty (60) days
from receiving the right to do so pursuant to this Section 16.5. In the event that EVOTEC fails to do so, EVOTEC’s right shall cease. For the avoidance of doubt, with respect to the time prior to the transfer of rights under
Section 17, such license and transfer pursuant to Section 17 will not release ROCHE from complying with its covenants as stipulated in Sections 16.2 and 16.3 nor from curing any non-compliance as determined as a result of the processes
stipulated in Sections 19.3 and 19.4. 
 17. Transfer of Rights 
 17.1 Prior to First Commercial Sale 
 If, prior to First Commercial Sale of the first Product in the Territory, the ROCHE
Group ceases all activities with regards to all Compounds and Products, then ROCHE shall (i) inform EVOTEC accordingly and (ii) if EVOTEC informs ROCHE of its decision to continue development and commercialization of Compounds and
Products, license to EVOTEC the ROCHE Patent Rights and ROCHE Know-How, (which will include the Patent Rights and Know-How generated by EVOTEC under the License Agreement, including the Joint Patent Rights, if any), relating to Compounds and
Products in the Field in the Territory, and transfer to EVOTEC all Patent Rights and Know-How that were included in the Assets relating to Compounds within clause (ii) of the definition of “Compound” in Section 1.10 or relating
to Products containing such a Compound. ROCHE shall, upon EVOTEC’s written request, to the extent it has the right to do so, transfer to EVOTEC, at no expense to EVOTEC, all regulatory filings and regulatory approvals, trademarks, and all data,
including clinical data, materials and information, in ROCHE’s possession and control related to Compounds and Products. 
 In such
case, the terms of the License Agreement shall apply, including future event payments and royalties. 
  

 29 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 Upon the request of EVOTEC, ROCHE shall complete any clinical studies related to the Products that are
being conducted under its IND for the Products and are ongoing as of the effective date of termination; provided, however, that 
  

	 	(a)	ROCHE may agree but shall have no obligation to recruit or enroll any additional patients after the ceasing of all activities under this Section 17.1; and

  

	 	(b)	EVOTEC agrees to reimburse ROCHE for all of its development costs which arise in completing such studies. 

 17.2 Within four (4) years from First Commercial Sale 
 If, within four (4) years from First Commercial Sale of the first Product in the Territory, the ROCHE Group ceases all activities with regards to all Compounds and Products, then ROCHE shall (i) inform EVOTEC accordingly and
(ii) if EVOTEC informs ROCHE of its decision to continue development and commercialization of Compounds and Products and pays to ROCHE a one-time, non-refundable and non-creditable transfer fee in the amount of US Dollar [***] (US$ [***]),
license to EVOTEC the ROCHE Patent Rights and ROCHE Know-How (which will include the Patent Rights and Know-How generated by EVOTEC under the License Agreement, including the Joint Patent Rights, if any), relating to Compounds and Products in the
Field in the Territory, and transfer to EVOTEC all Patent Rights and Know-How that were included in the Assets relating to Compounds within clause (ii) of the definition of “Compound” in Section 1.10 or relating to Products
containing such a Compound. 
 ROCHE shall, upon EVOTEC’s written request, to the extent it has the right to do so, transfer to EVOTEC,
at no expense to EVOTEC, all regulatory filings and regulatory approvals, trademarks, and all data, including clinical data, materials and information, in ROCHE’s possession and control related to Compounds and Products. 
 In such case, the terms of the License Agreement shall apply, including applicable event payments and royalties. 
 Upon the request of EVOTEC, ROCHE shall complete any clinical studies related to the Products that are being conducted under its IND for the Products and
are ongoing as of the effective date of termination; provided, however, that 
  

	 	(a)	ROCHE may agree but shall have no obligation to recruit or enroll any additional patients after the ceasing of all activities under this Section 17.2; and

  

	 	(b)	EVOTEC agrees to reimburse ROCHE for all of its development costs which arise in completing such studies. 

 17.3 After four (4) years from First Commercial Sale 
 After four (4) years from the First Commercial Sale of the first Product in the Territory, the ROCHE Group shall be free to cease all activities with regards to any and all Compounds and Products, without any compensation to EVOTEC.

 17.4 No further Payments 
 If ROCHE
transfers the rights under this Section 17, EVOTEC shall not be entitled to any further payments from ROCHE other than payments due on the day such right is exercised. For the avoidance of doubt, all payments already made to EVOTEC or due
pursuant to this Agreement up to the day ROCHE informs EVOTEC of its decision to cease all activities with regards to all Compounds and Products, shall remain with EVOTEC. 
  

 30 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 18. Termination 
 If the Option Right under the License Agreement expires or if ROCHE declines the Option Rights, as set forth in Section 3.1.2 or 3.1.3 of the License Agreement, then this Agreement shall automatically cease to
exist. 
 19. Miscellaneous 
 19.1 Confidentiality 

 The Parties recognize that the Assets and the results derived from the development and commercialization of the Compounds and the Products
constitute highly valuable and proprietary Confidential Information. EVOTEC agrees keep confidential, and will cause its employees, consultants, Affiliates to keep confidential, all Confidential Information and will only disclose such Confidential
Information in accordance with the terms of this Agreement, unless such information is in the public domain without breach of a confidentiality obligation towards ROCHE. 
 Neither Party may publicly disclose the existence or terms of this Agreement without the prior written consent of the other Party, provided, however, that either Party may make such a disclosure to the extent that it
is required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such Party has its securities listed or traded, to do so. In the event that such disclosure is required
as aforesaid, the disclosing Party shall make reasonable efforts to provide the other Party with notice in writing beforehand and to coordinate with the other Party with respect to the wording and timing of any such disclosure. The Parties, upon the
execution of this Agreement, will mutually agree to a press release with respect to the execution of the Agreement for publication. Once such press release or any other written statement is approved for disclosure by both Parties, either Party may
make subsequent public disclosure of the contents of such statement without the further approval of the other Party. 
 19.2 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of Switzerland, without reference to its conflict of laws principles, and
shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 
 19.3 Disputes

 Unless otherwise set forth in this Agreement, in the event of any dispute in connection with this Agreement, such dispute shall be
referred to the respective executive officers of the parties designated below or their designees, for good faith negotiations attempting to resolve the dispute. The designated executive officers are as follows: 
  

			
	 For EVOTEC:
	 	CEO
	 For ROCHE:
	 	Head of Pharma Partnering

 19.4 Arbitration 
 Should the parties fail to agree within two (2) months after such dispute has first arisen, it shall be finally settled by arbitration in accordance with the commercial arbitration rules of the International
Chamber of Commerce as in force at the time when initiating the arbitration. The tribunal shall consist of three arbitrators. The place of arbitration shall be Basel, Switzerland. The language to be used shall be English. 
  

 31 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 19.5 Assignment 
 Neither Party may assign its rights or obligations under this Agreement absent the prior written consent of the other Party, except to any of its Affiliates or in the context of a merger, acquisition, sale or other
transaction involving all or substantially all of the assets of the Party seeking to assign, in which case such Party in its sole discretion may assign its rights and obligations under this Agreement. Any permitted assignment shall be binding on the
successors of the assigning Party. 
 19.6 Independent Contractor 
 No employee or representative of either party shall have any authority to bind or obligate the other party to this Agreement for any sum or in any manner whatsoever or to create or impose any contractual or other
liability on the other party without said party’s prior written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, EVOTEC legal relationship to ROCHE under this Agreement shall be that of
independent contractor. 
 19.7 Rights of Retention and Set-off 
 The rights of retention and set-off of any of the Parties with regard to any payment claims or other liabilities under this Agreement are excluded and hereby expressly waived, unless 
  

	 	(i)	otherwise expressly provided in this Agreement, 

  

	 	    	or 

  

	 	(ii)	the underlying claims of the Party exercising such right are either undisputed or confirmed by a non-appealable decision. 

 19.8 Expenses and Fees 
 Each Party shall bear its own
costs and expenses in connection with the preparation, execution and implementation of this Agreement, including any and all professional fees of all of its advisers. 
 19.9 Unenforceable Provisions and Severability 
 If any of the provisions of this Agreement are held
to be void or unenforceable, then such void or unenforceable provisions shall be replaced by valid and enforceable provisions which will achieve as far as possible the economic business intentions of the parties. However the remainder of this
Agreement will remain in full force and effect, provided that the material interests of the parties are not affected, i.e. the parties would presumably have concluded this Agreement without the unenforceable provisions. 
 19.10 Waiver 
 The failure by either party to require
strict performance and/or observance of any obligation, term, provision or condition under this Agreement will neither constitute a waiver thereof nor affect in any way the right of the respective party to require such performance and/or observance.
The waiver by either party of a breach of any obligation, term, provision or condition hereunder shall not constitute a waiver of any subsequent breach thereof or of any other obligation, term, provision or condition. 
 19.11 Appendices 
 All Appendices to this Agreement
shall form an integral part to this Agreement. 
  

 32 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 19.12 Amendments 
 No amendments of the terms and conditions of this Agreement shall be binding upon either party hereto unless in writing and signed by authorized representatives of the parties. 
 19.13 Notice 
 All notices which are required or
permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by internationally recognized overnight courier
providing evidence of delivery or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	 if to EVOTEC, to:
	  	 Evotec Neurosciences GmbH
 Schnackenburgallee
114
 22525 Hamburg
 Germany
 Attn: Legal Department
 Facsimile No.: +49 40 560 81 333

		
	 if to ROCHE, to:
	  	 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland
 Attn: Legal Department
 Facsimile No.: +41 61 688 13 96

		
	 And:
	  	 Hoffmann-La Roche Inc.
 340 Kingsland
Street
 Nutley, New Jersey 07110
 U.S.A.
 Attn. Corporate Secretary
 Facsimile No.: +1 973 235-3500

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in
writing in accordance herewith. 
  

 33 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934. 

 IN WITNESS WHEREOF, the Parties have entered into this Agreement. 
  

							
	EVOTEC NEUROSCIENCES GmbH	  		 	
				
	By:	 	 /S/    JOHN A.
KEMP        
	  	By:	 	 /S/    K.
MALECK        

	Name:	 	John A. Kemp	  	Name:	 	Dr. K. Maleck
	Title:	 		  	Title:	 	CFO

  

							
	F. HOFFMANN-LA ROCHE LTD	  	March 9, 2009
				
	By:	 	 /S/    CHRISTOPHE
CARISSIMO        
	  	By:	 	 /S/    MELANIE FREY
WICK        

	Name:	 	Christophe Carissimo	  	Name:	 	Melanie Frey Wick
	Title:	 	Global Licensing Director	  	Title:	 	Legal Counsel

  

							
	HOFFMANN-LA ROCHE INC.	 	Apprv’d As To Form LAW DEPT.
				
	By:	 	 /S/    GEORGE W.
JOHNSTON        
	 	By:	 	 /S/    ILLEGIBLE        

	Name:	 	George W. Johnston	 		 	
	Title:	 	Vice President	 		 	

  

 34 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the 

Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 
 of the Securities Exchange Act of 1934.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]